[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 192
6. Sperti C, Pasquali C, Fiore V, Bissoli S, Chierichetti F, Liessi G, Pedrazzoli S: Clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the management of patients with nonpancreatic periampullary neoplasms. Am J Surg; 2006 Jun;191(6):743-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: 18-Fluorodeoxyglucose positron emission tomography (18-FDG PET) has been investigated for the diagnosis and staging of gastrointestinal malignancies including pancreatic adenocarcinoma.
  • Follow-up evaluation including CT scan and PET was performed in 12 patients: PET showed recurrent disease not seen by CT in 4 patients, confirmed CT findings in 6 patients, and showed an unsuspected primary lung cancer in 1 patient and colon cancer in another patient.
  • Finally, it is very useful in the follow-up evaluation of resected patients to identify recurrent disease or other malignancies.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720142.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


7. Ebi N, Semba H, Tokunaga SJ, Takayama K, Wataya H, Kuraki T, Yamamoto H, Akamine SJ, Okamoto I, Nakanishi Y, Lung Oncology Group in Kyushu, Japan: A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol; 2008 Oct;3(10):1166-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
  • BACKGROUND: Gefitinib has shown modest activity in patients with recurrent non-small cell lung cancer (NSCLC) after platinum-based chemotherapy.
  • Secondary endpoints were tolerability, disease-related symptom using lung cancer subscale (LCS) in FACT-L, progression free survival (PFS) and overall survival (OS).
  • Thirty-two patients were female (65%) and 40 patients had adenocarcinoma (82%).
  • There were four patients with possible interstitial lung disease including two treatment-related deaths.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Female. Health Surveys. Humans. Kaplan-Meier Estimate. Male. Maximum Tolerated Dose. Neoplasm Staging. Prognosis. Quality of Life. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / genetics. Survival Rate. Treatment Outcome


8. Nicolas MM, Nayar R, Yeldandi A, De Frias DV: Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report. Acta Cytol; 2006 Nov-Dec;50(6):672-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report.
  • We report a case of metastatic postradiation EAS to the lungs that was mistaken for adenocarcinoma.
  • Fine needle aspiration biopsy of the lung lesions showed round to oval tumor cells with amphophilic cytoplasm.
  • An interpretation of adenocarcinoma was rendered during assessment for specimen adequacy.
  • Review of the recurrent breast tumor (initially reported as DCIS) and a prior wedge resection of the lung nodules (reported as EAS) showed an epithelial-appearing tumor exhibiting an endothelial immunophenotype CONCLUSION: The cytologic features of EAS may resemble those of other neoplasms.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Hemangiosarcoma / secondary. Lung Neoplasms / secondary. Neoplasms, Radiation-Induced / pathology. Radiotherapy / adverse effects


9. Lind P, Kohlfürst S: Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med; 2006 Jul;36(3):194-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An increase of thyroglobulin over time is suspicious for recurrent or metastatic disease.
  • [MeSH-major] Adenocarcinoma, Follicular / radionuclide imaging. Carcinoma, Papillary / radionuclide imaging. Fluorodeoxyglucose F18. Iodine Radioisotopes. Positron-Emission Tomography. Radiopharmaceuticals. Thyroglobulin / blood. Thyroid Neoplasms / radionuclide imaging
  • [MeSH-minor] Biomarkers, Tumor / blood. Biopsy, Fine-Needle. Follow-Up Studies. Humans. Liver Neoplasms / radionuclide imaging. Liver Neoplasms / secondary. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / secondary. Lymphatic Metastasis / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Preoperative Care. Radiometry / methods. Sensitivity and Specificity. Thyroid Nodule / pathology. Thyroid Nodule / radionuclide imaging. Thyroid Nodule / ultrasonography. Thyrotropin. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16762610.001).
  • [ISSN] 0001-2998
  • [Journal-full-title] Seminars in nuclear medicine
  • [ISO-abbreviation] Semin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  • [Number-of-references] 82
  •  go-up   go-down


10. Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW: Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res; 2006 Jul 15;12(14 Pt 1):4283-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Specific activating mutations within the epidermal growth factor receptor (EGFR) identify a subset of non-small cell lung cancers with dramatic sensitivity to the specific tyrosine kinase inhibitors (TKI), gefitinib and erlotinib.
  • EXPERIMENTAL DESIGN: We sequenced exons 18 to 21 of EGFR from 21 cases of Barrett's esophagus, 5 cases of high-grade esophageal dysplasia, 17 cases of esophageal adenocarcinoma, and 55 cases of pancreatic adenocarcinoma.
  • The mutations consisted of the recurrent missense L858R and in-frame deletion delE746-A750, previously characterized as activating EGFR mutations in non-small cell lung cancer.
  • We also identified the TKI drug resistance-associated EGFR T790M mutation in an untreated case of Barrett's esophagus and the corresponding adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93 [15731348.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2244-51 [15788673.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2493-501 [15710947.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2513-20 [15738541.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2879-82 [15837736.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3750-7 [15897572.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70 [15897464.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1081-6 [15851406.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e73 [15737014.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1334-42 [15956035.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5539-48 [16061871.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7096-101 [16103058.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7568-72 [16140919.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6838-45 [15998906.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6829-37 [15998907.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6816-22 [16203769.001]
  • [Cites] Ann Oncol. 2005 Nov;16(11):1848-9 [16012179.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Oct;131(10):649-52 [16032426.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8081-92 [16204011.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8105-8 [16299242.001]
  • [Cites] Nat Genet. 2005 Dec;37(12):1315-6 [16258541.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8418-24 [16322304.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):963-9 [16152581.001]
  • [Cites] Oncogene. 2006 Feb 23;25(8):1205-15 [16205628.001]
  • [Cites] Cancer Biol Ther. 2006 Feb;5(2):152-5 [16357520.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4922-7 [17050876.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Science. 2002 Jul 5;297(5578):63-4 [12098689.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1980-7 [12743152.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4819-25 [14581353.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):11-6 [15261138.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7241-4 [15492241.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):213-9 [8098013.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8195-203 [15623594.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2883 [15625347.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):226-35 [15665299.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1167-73 [15709185.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):786-92 [15728811.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1368-71 [15746034.001]
  • (PMID = 16857803.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK071329; United States / NCI NIH HHS / CA / R01 CA115830; United States / PHS HHS / / P01 95281; United States / NCI NIH HHS / CA / R01 CA11530
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS519524; NLM/ PMC3807136
  •  go-up   go-down


11. Casali C, Rossi G, Marchioni A, Sartori G, Maselli F, Longo L, Tallarico E, Morandi U: A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice. J Thorac Oncol; 2010 Jun;5(6):830-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice.
  • METHODS: Retrospective analysis of resected BAC reclassified according to the 2004 World Health Organization classification of lung tumors.
  • Sixty six percent (4 of 6) of patients with multifocal disease died (two mucinous BAC and one nonmucinous BAC with recurrent disease).
  • Seventy one percent (5 of 7) of patients with pneumonic-like tumor (all mucinous BAC) died of recurrent/progressive disease.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20521350.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


12. Gómez-Román JJ, Del Valle CE, Zarrabeitia MT, Martínez JC, Goñi FZ, Lera RM, Cuevas J, Val-Bernal JF: Recurrence of bronchioloalveolar carcinoma in donor lung after lung transplantation: microsatellite analysis demonstrates a recipient origin. Pathol Int; 2005 Sep;55(9):580-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of bronchioloalveolar carcinoma in donor lung after lung transplantation: microsatellite analysis demonstrates a recipient origin.
  • Bronchioloalveolar carcinoma is a distinctive subtype of pulmonary adenocarcinoma, without effective therapy, although there have recently been some attempts to use lung transplantation.
  • Presented herein is a case of a bilateral lung transplantation for a bilateral and pneumonic form of non-mucinous bronchioloalveolar carcinoma in a 43-year-old woman.
  • A complete microsatellites molecular analysis was performed to compare the primary and recurrent carcinoma using capillary electrophoresis, showing that the recurrent tumor was generated in a recipient cellular clone.
  • The absence of lymph node metastasis and the molecular evidence of the recipient origin of the neoplasm supports the contamination of the new lungs at the time of implantation as being the reason for the high incidence of recurrence after lung transplantation in this kind of disease.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / surgery. Lung Neoplasms / surgery. Lung Transplantation. Microsatellite Repeats. Neoplasm Recurrence, Local / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16143034.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


13. Maeda T, Tateishi U, Komiyama M, Fujimoto H, Watanabe S, Terauchi T, Moriyama N, Arai Y, Sugimura K, Kakizoe T: Distant metastasis of prostate cancer: early detection of recurrent tumor with dual-phase carbon-11 choline positron emission tomography/computed tomography in two cases. Jpn J Clin Oncol; 2006 Sep;36(9):598-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distant metastasis of prostate cancer: early detection of recurrent tumor with dual-phase carbon-11 choline positron emission tomography/computed tomography in two cases.
  • In one patient, recurrent tumor of the supraclavicular node (6 mm) diminished in size after subsequent hormone therapy.
  • Surgical resection of recurrent tumor of the lung (12 mm) was performed in the other patient, the pathology of which confirmed the metastatic adenocarcinoma derived from the prostate.
  • The recurrent tumor can be correctly detected by dual-phase whole body [C-11] choline positron emission tomography/computed tomography.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / radionuclide imaging. Lymph Nodes / pathology. Lymphatic Metastasis / radionuclide imaging. Pelvic Neoplasms / radionuclide imaging. Positron-Emission Tomography. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844733.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Carbon Radioisotopes; EC 3.4.21.77 / Prostate-Specific Antigen; N91BDP6H0X / Choline
  •  go-up   go-down


1
Advertisement
4. David A, Blotta A, Rossi R, Zatelli MC, Bondanelli M, Roti E, Braverman LE, Busutti L, degli Uberti EC: Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid; 2005 Feb;15(2):158-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-seven patients had high positive rhTSH Tg testing and (131)I uptake was detected in lung, bone, or mediastinum in 11.
  • In conclusion, our results suggest that any rise in rhTSH-Tg, even at low level, should raise the suspicion of persistent or recurrent DTC.
  • [MeSH-minor] Adenocarcinoma, Follicular / radionuclide imaging. Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Follicular / surgery. Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Iodine Radioisotopes. Male. Middle Aged. Neoplasm, Residual / pathology. Neoplasm, Residual / radionuclide imaging. Postoperative Complications / drug therapy. Recombinant Proteins / therapeutic use. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Thyroid. 2006 May;16(5):517-9 [16756477.001]
  • (PMID = 15753676.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Recombinant Proteins; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


15. Shimomura T, Ikemoto I, Yamada H, Hayashi N, Ito H, Oishi Y: Sarcomatoid renal cell carcinoma with a chromophobe component producing beta-human chorionic gonadotropin. Int J Urol; 2005 Sep;12(9):835-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, 3 months later, masses were discovered in the left renal bed and in the lung in association with elevated serum levels of beta-HCG.
  • The recurrent mass responded extremely well to treatment, and beta-HCG normalized.
  • Sarcomatoid renal cell carcinoma is a variant of renal adenocarcinoma which has a poor prognosis.

  • Genetic Alliance. consumer health - Chromophobe Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Urol. 2006 Jan;13(1):99
  • (PMID = 16201981.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


16. Hsieh CT, Chang CF, Liu MY, Chang LP, Hueng DY, Chang SD, Ju DT: Successful treatment of metastatic brain tumor by CyberKnife: a case report. Kaohsiung J Med Sci; 2010 Mar;26(3):144-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report a case of adenocarcinoma of lung that had metastasized to the brain.
  • A dramatic response was noted 3 months after radiosurgery with complete disappearance of the recurrent tumor.
  • [MeSH-minor] Humans. Lung Neoplasms / pathology. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20227654.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


17. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, Nakagawara A, Hayashi Y, Mano H, Ogawa S: Oncogenic mutations of ALK kinase in neuroblastoma. Nature; 2008 Oct 16;455(7215):971-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we show that the anaplastic lymphoma kinase (ALK), originally identified as a fusion kinase in a subtype of non-Hodgkin's lymphoma (NPM-ALK) and more recently in adenocarcinoma of lung (EML4-ALK), is also a frequent target of genetic alteration in advanced neuroblastoma.
  • According to our genome-wide scans of genetic lesions in 215 primary neuroblastoma samples using high-density single-nucleotide polymorphism genotyping microarrays, the ALK locus, centromeric to the MYCN locus, was identified as a recurrent target of copy number gain and gene amplification.


18. Martinez-Glez V, Bello MJ, Franco-Hernandez C, De Campos JM, Isla A, Vaquero J, Rey JA: Mutational analysis of the DAL-1/4.1B tumour-suppressor gene locus in meningiomas. Int J Mol Med; 2005 Oct;16(4):771-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The DAL-1/41B gene (differentially expressed in adenocarcinoma of the lung), located in the chromosome 18p11.3 region, belongs to the protein family 4.1 (membrane-associated proteins), which includes the product of the NF2 gene (merlin), and the proteins, ezrin, radixin, and moesin.
  • The similarity between the DAL-1/4.1B protein and merlin, with their high levels of expression in the brain and their recurrent loss in meningiomas, and the lack of previous DAL-1/4.1B mutational analysis reports initiated this mutational study of DAL-1/4.1B in a series of 83 meningiomas.
  • We found the following sequence variations; Ala555Thr (G1663A in exon 13) and Thr950Lys (C2849A in exon 19) in two cases each, and one case with a 5pb deletion (del taaaa) in intron 18.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142420.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / EPB41L3 protein, human; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


19. Kosmas C, Tsavaris N, Syrigos K, Koutras A, Tsakonas G, Makatsoris T, Mylonakis N, Karabelis A, Stathopoulos GP, Kalofonos HP: A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Cancer Chemother Pharmacol; 2007 Jan;59(1):51-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
  • PURPOSE: Treatment options in patients with recurrent non-small cell lung cancer (NSCLC) remain limited as a result of poor activity of most agents after failure of platinum-based therapy.
  • RESULTS: Forty-nine patients entered the phase I and II part of the study (phase I: 12-phase II: 37 + 3 at DL-3), and 40 patients were evaluable for a response in phase II and all for toxicity: median age, 61 years (range 36-74); PS, 1 (0-2); gender, 43 males/6 females-histologies; adenocarcinoma, 25; squamous, 20; large cell, 4.
  • Metastatic sites included lymph nodes, 38; bone, 5; liver, 4; brain, 3; lung nodules, 14; adrenals, 13; other, 3.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622691.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Bridged Compounds; 0 / Organoplatinum Compounds; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 1605-68-1 / taxane; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


20. Conigliaro R, Battaglia G, Repici A, De Pretis G, Ghezzo L, Bittinger M, Messmann H, Demarquay JF, Togni M, Blanchi S, Filiberti R, Conio M: Polyflex stents for malignant oesophageal and oesophagogastric stricture: a prospective, multicentric study. Eur J Gastroenterol Hepatol; 2007 Mar;19(3):195-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cause of obstruction was oesophageal squamous cell carcinoma (44) and adenocarcinoma (eight), lung cancer (seven) and thyroid tumour (one).
  • Recurrent dysphagia for early stent migration was observed in seven patients.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301645.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Plastics
  •  go-up   go-down


21. Tsurumaki H, Tomizawa Y, Tsuchiya T, Suzuki J, Iijima H, Yoshii A, Watanabe S, Sato K, Kamide Y, Mori M, Saito R: [A case of non-small cell lung cancer responding to S-1 over a year]. Gan To Kagaku Ryoho; 2010 Nov;37(11):2147-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of non-small cell lung cancer responding to S-1 over a year].
  • After extensive examination, she was diagnosed with primary lung adenocarcinoma (cT4N2M1, stage IV).
  • Therefore, oral administration of S-1 could be useful for the treatment of recurrent non-small cell lung cancer over a long time.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21084815.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


22. Ross HJ, Blumenschein GR Jr, Aisner J, Damjanov N, Dowlati A, Garst J, Rigas JR, Smylie M, Hassani H, Allen KE, Leopold L, Zaks TZ, Shepherd FA: Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res; 2010 Mar 15;16(6):1938-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
  • PURPOSE: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non-small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history.
  • EXPERIMENTAL DESIGN: Patients with good performance status and recurrent or metastatic NSCLC were randomized to lapatinib (orally, 1,500 mg once daily or 500 mg twice daily) until progression or intolerance.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Drug Resistance, Neoplasm. Female. Humans. Middle Aged. Neoplasm Metastasis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / antagonists & inhibitors. Receptor, ErbB-2 / metabolism. Salvage Therapy. Survival Rate. Treatment Outcome


23. Bizekis C, Kent MS, Luketich JD, Buenaventura PO, Landreneau RJ, Schuchert MJ, Alvelo-Rivera M: Initial experience with minimally invasive Ivor Lewis esophagectomy. Ann Thorac Surg; 2006 Aug;82(2):402-6; discussion 406-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for esophagectomy included short segment Barrett's esophagus with high-grade dysplasia or resectable adenocarcinoma of the gastroesophageal junction (GEJ) with minimal proximal esophageal extension. .
  • There were no recurrent laryngeal nerve injuries.
  • This approach minimizes the degree of gastric mobilization, almost eliminates recurrent laryngeal nerve injury and pharyngeal dysfunction, and allows additional gastric resection margin in the case of cardia extension of GEJ tumors.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16863737.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Ozlü T, Bülbül Y: Smoking and lung cancer. Tuberk Toraks; 2005;53(2):200-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smoking and lung cancer.
  • The association between cigarettes and lung cancer has been proven by large cohort studies.
  • Tobacco use has been reported to be the main cause of 90% of male and 79% of female lung cancers.
  • 90% of deaths from lung cancer are estimated to be due to smoking.
  • The risk of lung cancer development is 20-40 times higher in lifelong smokers compared to non-smokers.
  • In recent decades, there has been a shift from squamous and small cell lung cancer types to adenocarcinoma, due to increasing rates of smoking among female population and rising light cigarette usage.
  • After smoking cessation, the cumulative death risk from lung cancer decreases.
  • Stopping smoking may prolong survival in cancer patients, and also decreases the risk of recurrent pulmonary carcinoma.
  • [MeSH-major] Lung Neoplasms / prevention & control. Smoking / adverse effects. Smoking Cessation


25. Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, Choi HJ, Kim YJ, Shin SJ, Sohn JH, Kim H, Kim JH: Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol; 2007 Jun 20;25(18):2528-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
  • PURPOSE: This study was designed to evaluate the efficacy and toxicity of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) who experienced disease progression after treatment with gefitinib.
  • PATIENTS AND METHODS: The study included stage IIIB/IV recurrent or metastatic NSCLC patients who received two or three prior chemotherapy regimens and showed progressive disease within 4 months of gefitinib therapy discontinuation.
  • RESULTS: Patient and disease characteristics (N = 21) included median age 56 years; number of prior chemotherapy regimens (three; n = 11); female sex (n = 11); adenocarcinoma (n = 15); and never-smoker status (n = 11).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use


26. Lee BE, Port JL, Stiles BM, Saunders J, Paul S, Lee PC, Altorki N: TNM stage is the most important determinant of survival in metachronous lung cancer. Ann Thorac Surg; 2009 Oct;88(4):1100-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNM stage is the most important determinant of survival in metachronous lung cancer.
  • BACKGROUND: Distinguishing a metachronous lung cancer from a metastatic or recurrent lesion in patients with a prior history of non-small cell lung cancer is a challenging task.
  • Previous studies have suggested histologic type and disease-free interval as criteria for diagnosing metachronous lung cancer.
  • These factors may not be as relevant now that current imaging allows for earlier detection of tumors and with the rising incidence of adenocarcinoma.
  • The purpose of this study was to reexamine the factors that determine outcomes in patients with a second primary lung cancer.
  • METHODS: A retrospective review of a prospective lung cancer database was performed to identify patients with metachronous lung cancer.
  • Metachronous lung cancer was defined as any non-small cell lung cancer occurring after a prior resection regardless of disease-free interval or histologic type.
  • RESULTS: Fifty-eight patients had metachronous lung cancer.
  • CONCLUSIONS: These data suggest that early tumor stage is the only significant determinant of survival after surgical treatment of metachronous lung cancer.
  • [MeSH-major] Lung Neoplasms / mortality. Neoplasm Staging / methods. Neoplasms, Second Primary / mortality

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19766788.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


27. Carpentier A, McNichols RJ, Stafford RJ, Itzcovitz J, Guichard JP, Reizine D, Delaloge S, Vicaut E, Payen D, Gowda A, George B: Real-time magnetic resonance-guided laser thermal therapy for focal metastatic brain tumors. Neurosurgery; 2008 Jul;63(1 Suppl 1):ONS21-8; discussion ONS28-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance-guided laser-induced thermal therapy appears to provide a new, efficient treatment for recurrent focal metastatic brain disease.
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Aged. Breast Neoplasms / pathology. Female. Follow-Up Studies. Humans. Lung Neoplasms / pathology. Male. Middle Aged. Monitoring, Intraoperative / instrumentation. Monitoring, Intraoperative / methods. Pilot Projects. Stereotaxic Techniques / instrumentation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728600.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2 R44 CA079282; United States / NCI NIH HHS / CA / 2 R44 CA101573; United States / NCI NIH HHS / CA / 2 R44 CA96227; United States / NIA NIH HHS / AG / 5 R44 AG019276
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


28. Togashi K, Hosaka Y, Okada A, Sato S: [Iterative surgical resections for second primary and local recurrent lung cancer; comparison of lobectomy and limited resection]. Kyobu Geka; 2010 Oct;63(11):963-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Iterative surgical resections for second primary and local recurrent lung cancer; comparison of lobectomy and limited resection].
  • During a 24-year period (1986-2009), 74 patients (3.5%) underwent iterative surgical resections for 2nd primary and recurrent lung cancer.
  • Patients are classified to 5 groups: 20 2nd primary lung cancer patients undergoing lobectomy (A), 24 2nd primary lung cancer patients undergoing limited resection (B), 11 2nd primary bronchioloalveolar carcinoma (BAC) patients undergoing limited resection (C), 8 recurrent lung cancer patients undergoing lobectomy (D), and 11 recurrent lung cancer patients undergoing limited resection (E).
  • There were 18 (90%) patients with adenocarcinoma in group A, 15 (63%) in B, 11 (100%) in C, 5 (63%) in D, and 9 (82%) in E.
  • These data showed that limited resections had low surgical risk and good long-term results.
  • Limited resection appears to achieve better outcomes for 2nd primary and recurrent lung cancer and should be chosen whenever possible.
  • [MeSH-major] Lung Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / surgery. Pneumonectomy / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20954351.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


29. Okamoto T, Maruyama R, Seto T, Yamazaki K, Wataya H, Nishiyama K, Ichinose Y: Multiple pulmonary metastases of lung adenocarcinoma to a different ipsilateral lobe after pulmonary lobectomy. Lung Cancer; 2007 Jun;56(3):449-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple pulmonary metastases of lung adenocarcinoma to a different ipsilateral lobe after pulmonary lobectomy.
  • Pulmonary metastases (PM) to different lobes are classified as M1 disease in non-small cell lung cancer.
  • We report on three patients with lung adenocarcinoma who had undergone complete resection as the initial treatment and thereafter had recurrence of multiple PMs but only in a different ipsilateral lobe 19, 9, and 6 months after surgery.
  • Two patients underwent completion pneumonectomy for the ipsilateral recurrent PM and are doing well without recurrence at 7 and 1 year after the second operations.
  • Our findings suggest that some patients with recurrent multiple PM limited to a different ipsilateral lobe have a good prognosis with aggressive treatment, including surgery, and suggest that the PM in such patients occurs through a local route within the ipsilateral thorax.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Neoplasm Recurrence, Local. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17300852.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


30. Sawada T, Nishimura M, Hirose K: [Long-term survival in a case of large bowel cancer--efficacy of CPT-11-based chemotherapy]. Gan To Kagaku Ryoho; 2005 Jul;32(7):1059-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survival in a case of large bowel cancer--efficacy of CPT-11-based chemotherapy].
  • It thus may be an effective regimen for advanced and recurrent large bowel cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Floxuridine / administration & dosage. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Mitomycin / administration & dosage. Peritoneal Neoplasms / secondary. Survivors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044974.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; 50SG953SK6 / Mitomycin; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; V1JK16Y2JP / doxifluridine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


31. Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Jänne PA, Bonomi P: Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol; 2006 Nov 20;24(33):5253-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.
  • PURPOSE: To determine the efficacy of cetuximab in patients with recurrent or progressive non-small-cell lung cancer (NSCLC) after receiving at least one prior chemotherapy regimen.
  • RESULTS: Patient and disease characteristics (n = 66) included EGFR-positive status (n = 60); EGFR-negative status (n = 6); number of prior regimens (one, n = 28; two, n = 27; > or = three, n = 11); male (n = 41); female (n = 25); adenocarcinoma (n = 36); and smoking status (never, n = 13; former, n = 45; current, n = 8).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy


32. Suzuki S, Sekikawa K, Fujita S, Abe N, Ishigame T, Okada R, Gonda K, Saito M, Onogi H, Ohki S, Takenoshita S: [A case of recurrent gastric cancer effectively treated by combination chemotherapy of weekly paclitaxel and 5'- DFUR after showing resistance to weekly paclitaxel]. Gan To Kagaku Ryoho; 2006 Mar;33(3):385-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent gastric cancer effectively treated by combination chemotherapy of weekly paclitaxel and 5'- DFUR after showing resistance to weekly paclitaxel].
  • The patient was a 35-year-old woman with lung, bone and lymphnode metastases of gastric cancer after a total gastrectomy two years earlier.
  • After 3 courses, the size of the lung metastasis was remarkably decreased.
  • This case suggests that combination chemotherapy of weekly paclitaxel and 5'-DFUR might be a promising regimen for recurrent gastric cancer even for patients who show no effect with only paclitaxel administration.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Floxuridine / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Bone Neoplasms / secondary. Combined Modality Therapy. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Gastrectomy. Humans. Lung Neoplasms / secondary. Lymph Node Excision. Paclitaxel / administration & dosage. Paclitaxel / pharmacology. Quality of Life

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531725.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


33. Da Ines D, Chabrot P, Cassagnes L, Merle P, Filaire M, Ravel A, Garcier JM, Boyer L: [Endovascular treatment of SVC syndrome from neoplastic origin: a review of 34 cases]. J Radiol; 2008 Jul-Aug;89(7-8 Pt 1):881-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Traitement endovasculaire du syndrome cave supérieur d'origine néoplasique: à propos de 34 patients.
  • MATERIALS AND METHODS: Thirty-four patients were treated between January 2000 and February 2007: 21 males and 13 females, aged 44-81 years, with non-small-cell lung carcinoma in 27 cases (79%), small-cell lung carcinoma in 5 cases (15%) and metastatic breast adenocarcinoma to the mediastinum in 2 cases (6%).
  • Five patients with recurrent SVC syndrome underwent repeat treatment (restenosis in 3 cases, fracture in 1 case, thrombosis in 1 case), for primary and secondary patency rates of 81% and 100%.
  • CONCLUSION: Palliative stent treatment of neoplastic SVC syndrome is reliable, safe and provides long-standing improvement in quality of life.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lung Neoplasms / complications. Male. Mediastinal Neoplasms / complications. Middle Aged

  • MedlinePlus Health Information. consumer health - Angioplasty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18772750.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


34. Mori N, Sawada T, Satoh H, Kawaguchi M, Hara H, Matsushita K: A resected case of solitary pancreatic metastasis from adenocarcinoma of the lung. JOP; 2008;9(6):698-703
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A resected case of solitary pancreatic metastasis from adenocarcinoma of the lung.
  • CONTEXT: Primary lung cancer frequently metastasizes to distant organs; however, the pancreas is a relatively infrequent site of metastasis.
  • Most patients demonstrate accompanying metastases to other organs, especially in cases of lung cancer, which prove to be surgically unresectable when diagnosed.
  • Although several cases have been reported of patients who underwent pancreatic resection for curative intent, most patients died from recurrent disease.
  • CASE REPORT: We report herein an unusual case of secondary tumor of the pancreas (primary tumor: adenocarcinoma of the lung) with hopefully curative resection.
  • The interval between the surgical treatment of lung cancer and the metachronous pancreatic metastasis was 22 months; there has been no recurrence of disease during the 24 months of follow-up after a pylorus-preserving pancreaticoduodenectomy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981550.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


35. Yano T, Haro A, Yoshida T, Morodomi Y, Ito K, Shikada Y, Shoji F, Maruyama R, Maehara Y: Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer. J Surg Oncol; 2010 Dec 1;102(7):852-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer.
  • OBJECTIVES: In this study, we investigated prognostic factors associated with survival after distantly metastatic recurrence in surgically resected non-small cell lung cancer (NSCLC), and clarified the influence of local treatment on the prognosis for oligometastatic recurrence.
  • Their recurrent disease (oligometastases) was limited with the potential to be controlled with local treatment.
  • Significant prognostic factors for postrecurrence survival included adenocarcinoma histology, long disease-free interval (DFI) (1 year or longer), and the performance of local treatment for oligometastases.
  • [MeSH-major] Bone Neoplasms / surgery. Brain Neoplasms / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Neoplasm Recurrence, Local / surgery


36. Kondo M, Yokoyama T, Fukui T, Yoshioka H, Yokoi K, Nagasaka T, Imaizumi K, Kume H, Hasegawa Y, Shimokata K, Sekido Y: Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. Lung Cancer; 2005 Dec;50(3):385-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
  • The epidermal growth factor receptor (EGFR) gene has recently been reported to be mutated in a subset of non-small cell lung cancers (NSCLC), with the mutations being correlated with the patients' drug sensitivity to gefitinib, an EGFR kinase inhibitor.
  • In this study, we searched for EGFR mutations in patients with lung cancer using primary tumor specimens obtained at initial surgery and examined whether their recurrent tumors showed a response to gefitinib depending on the presence of the activating mutation.
  • Among 12 lung cancers that were treated with gefitinib after recurrence, we found that all four tumors which showed a response to gefitinib had an activating mutation in EGFR, whereas none of the remaining eight tumors had a mutation.
  • Comparing the alterations in KRAS and P53 with the EGFR mutation, we found that 10 tumors with the KRAS mutation did not have an EGFR mutation, suggesting that each mutation occurs exclusively during the development of lung cancer.
  • These results suggest that the mutation analysis of the EGFR gene using the specimens obtained at surgery might be useful in selecting the appropriate treatment(s) for recurrent lung cancer patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / drug therapy. Lung Neoplasms / genetics. Mutation / genetics. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / etiology. Adenocarcinoma / genetics. Adenocarcinoma / surgery. Aged. Base Sequence. Combined Modality Therapy. DNA, Neoplasm / analysis. DNA, Neoplasm / genetics. Female. Gene Amplification. Genes, ras. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Sensitivity and Specificity. Sex Characteristics


37. Tew WP, Kelsen DP, Ilson DH: Targeted therapies for esophageal cancer. Oncologist; 2005 Sep;10(8):590-601
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In fact, gastric and esophageal cancers together accounted for nearly 1.3 million new cases and 980,000 deaths worldwide in 2000-more than lung, breast, or colorectal cancer.
  • Although esophageal squamous cell carcinoma cases have steadily declined, the incidence of gastroesophageal junction adenocarcinoma has increased 4%-10% per year among U.S. men since 1976, more rapidly than for any other cancer type, and parallels rises in population trends in obesity and reflux disease.
  • (c) high risk for recurrent disease after esophagectomy or definitive chemoradiotherapy;.
  • This review focuses on novel targeted treatments in development for esophageal squamous cell carcinoma and distal esophageal and gastroesophageal junction adenocarcinoma.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177283.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cyclooxygenase 2 Inhibitors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Number-of-references] 128
  •  go-up   go-down


38. Martoni AA, Melotti B, Sperandi F, Giaquinta S, Piana E, Pavesi L, Da Prada G, Lelli G: Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study. Lung Cancer; 2008 Jun;60(3):387-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study.
  • /oral (hybrid) administration of vinorelbine (VNR) plus cisplatin (CDDP), followed by oral VNR, could result in a more suitable first-line regimen for patients (pts) with advanced non-small cell lung cancer (aNSCLC) in the outpatient setting.
  • RESULTS: Fifty-three pts entered the study: 80% males; median age 63 years (range 43-71); median ECOG PS 0 (range 0-1); histotype: adenocarcinoma 59%, epidermoid 31%, undifferentiated 10%; disease stage: IIIB 22%, IV 70%, recurrent disease 8%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / administration & dosage. Lung Neoplasms / drug therapy. Vinblastine / analogs & derivatives


39. Koenig MA, Maleszewski J, Winters B: Multiple hemorrhagic strokes from DIC associated with occult large cell carcinoma. Neurocrit Care; 2006;5(3):210-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over the hospital course, he suffered recurrent ischemic strokes and intracerebral hemorrhages despite management of his coagulopathy.
  • CONCLUSIONS: Recurrent hemorrhagic strokes associated with DIC may be the initial presentation of occult malignancy.
  • Although adenocarcinoma is classically associated with paraneoplastic DIC, this case demonstrates that large cell carcinoma may also be implicated.
  • [MeSH-minor] Aged. Diagnosis, Differential. Fibrin Fibrinogen Degradation Products / metabolism. Humans. International Normalized Ratio. Lung / pathology. Lung Neoplasms / pathology. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1990 Apr;17(2):172-86 [2183359.001]
  • [Cites] Stroke. 2004 Feb;35(2):533-7 [14707231.001]
  • [Cites] Cerebrovasc Dis. 2002;14(3-4):266-7 [12403965.001]
  • [Cites] Thromb Haemost. 2001 Sep;86(3):828-33 [11583315.001]
  • [Cites] Neurol Clin. 2003 Feb;21(1):167-92 [12690649.001]
  • [Cites] J Clin Invest. 1993 Sep;92(3):1207-12 [8376580.001]
  • [Cites] N Engl J Med. 2000 Jun 15;342(24):1773-7 [10852999.001]
  • [Cites] Thromb Haemost. 1999 Aug;82(2):695-705 [10605770.001]
  • [Cites] N Engl J Med. 1998 Nov 26;339(22):1585-94 [9828246.001]
  • [Cites] Nat Med. 1996 Feb;2(2):209-15 [8574967.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Aug;10(4):875-907 [8811307.001]
  • [Cites] Blood. 1989 Jul;74(1):165-72 [2752108.001]
  • [Cites] Am J Hematol. 1998 Sep;59(1):65-73 [9723580.001]
  • (PMID = 17290091.001).
  • [ISSN] 1541-6933
  • [Journal-full-title] Neurocritical care
  • [ISO-abbreviation] Neurocrit Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrin Fibrinogen Degradation Products; 0 / fibrin fragment D
  •  go-up   go-down


40. Abe T, Hayashi M, Tsutsui N, Ito K, Haraguchi M: [Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2006 Feb;44(2):144-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer].
  • "Case 1" A 56-year-old woman who suffered from postoperative recurrent non-small cell lung cancer received gefitinib therapy.
  • "Case 2" A 46-year-old man with stage IV non-small cell lung cancer started gefitinib therapy after chemotherapy.
  • It has been reported that the central nervous system is a frequent metastatic site of non-small cell lung cancer in patients treated with gefitinib.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / etiology. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Meningeal Neoplasms / etiology. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Disease Progression. Fatal Outcome. Female. Humans. Male. Middle Aged


41. Ferrer Rebolleda J, Ortega de los Mártires F, Santos Cores J, Menéndez López A, Arribas Alpuente L, Almenar Medina S: [Contribution of PET in the follow-up of cerebral metastases in non-small cell lung cancer. A clinical case valuation]. Rev Esp Med Nucl; 2006 Mar-Apr;25(2):107-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Contribution of PET in the follow-up of cerebral metastases in non-small cell lung cancer. A clinical case valuation].
  • [Transliterated title] Aportación de la PET en el seguimiento de las metástasis cerebrales del cáncer de pulmón no microcítico. Valoración de un caso clínico.
  • We report a clinical case of a male 44 years old with lung adenocarcinoma with a single brain metastases treated with surgery and radiotherapy.
  • The different PET studies performed during the evolution of the disease were very useful and crucial, firstly in the detection of radiation necrosis and after that when cerebral metastases recurrent appeared twice.
  • PET imaging is helpful in selected patients with brain metastases in lung cancer.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Adenocarcinoma / secondary. Brain Neoplasms / radionuclide imaging. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Carcinoma, Non-Small-Cell Lung / secondary. Frontal Lobe / radionuclide imaging. Lung Neoplasms / pathology. Parietal Lobe / radionuclide imaging. Positron-Emission Tomography


42. Iwata T, Inoue K, Morita R, Tsukioka T, Yamoto M, Suehiro S: Acute nonbacterial pleuritis caused by spontaneous rupture of metastatic pulmonary adenocarcinoma. Gen Thorac Cardiovasc Surg; 2008 Jul;56(7):347-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute nonbacterial pleuritis caused by spontaneous rupture of metastatic pulmonary adenocarcinoma.
  • Nonbacterial pleuritis caused by rupture of a metastatic adenocarcinoma is extremely rare and has not yet been reported.
  • A 59-year-old man with a history of rectal cancer surgery 6 years earlier presented with a solitary lung mass in the periphery of the right lower lobe on computed tomography.
  • Transbronchial biopsy disclosed a suspected metastatic adenocarcinoma, and he was admitted for pulmonary metastasectomy.
  • The postoperative course was uneventful, and he was well without recurrent disease 2 years after pulmonary resection.
  • [MeSH-major] Adenocarcinoma / complications. Colorectal Neoplasms / pathology. Lung Neoplasms / complications. Pleurisy / etiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2006;36(10):919-22 [16998687.001]
  • [Cites] J Am Geriatr Soc. 2006 May;54(5):827-30 [16696751.001]
  • [Cites] Am J Gastroenterol. 1996 Sep;91(9):1865-6 [8792722.001]
  • [Cites] Surg Today. 2000;30(5):469-72 [10819490.001]
  • [Cites] Cancer. 1982 Apr 15;49(8):1734-7 [6950803.001]
  • (PMID = 18607683.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


43. Kagohashi K, Nakayama H, Kagei K, Kurishima K, Ishikawa H, Satoh H: Thoracic radiotherapy for mediastinal nodal recurrence. Acta Medica (Hradec Kralove); 2009;52(1):23-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiotherapy has been used to treat loco-regional recurrences located at various intra-thoracic sites, but long-term survival of these patients has been rarely observed.
  • We report herein a lung adenocarcinoma patient with locoregional recurrence, who was successfully treated with high-dose radiotherapy.
  • It is probably safe to administrate high-dose radiotherapy for some loco-regional recurrent patients with favorable prognostic factors such as good PS, no body weight loss.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19754004.001).
  • [ISSN] 1211-4286
  • [Journal-full-title] Acta medica (Hradec Kralove)
  • [ISO-abbreviation] Acta Medica (Hradec Kralove)
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


44. Gerosa M, Nicolato A, Foroni R, Tomazzoli L, Bricolo A: Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery. J Neurosurg; 2005 Jan;102 Suppl:75-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery.
  • OBJECT: The authors conducted a study to evaluate the long-term outcomes and prognostic factors for survival in a large series of patients treated by gamma knife surgery (GKS) for non-small cell lung cancer (NSCLC) brain metastases.
  • The lesions were primary in 86% and recurrent 14% of the cases; they were solitary in 31%, single in 29%, and multiple in 40%.
  • The most common histological types were adenocarcinoma (51%) and squamous cell carcinoma (27%).
  • Analysis of long-term outcomes seemed to confirm that GKS is a primary therapeutic option in these patients.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Radiosurgery / instrumentation


45. Isobe K, Hata Y, Takai Y, Shibuya K, Takagi K, Homma S: Usefulness of fluoro-2-deoxyglucose positron emission tomography for investigating unexplained rising carcinoembryonic antigen levels that occur during the postoperative surveillance of lung cancer patients. Int J Clin Oncol; 2009 Dec;14(6):497-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of fluoro-2-deoxyglucose positron emission tomography for investigating unexplained rising carcinoembryonic antigen levels that occur during the postoperative surveillance of lung cancer patients.
  • BACKGROUND: Positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) has been useful for the detection of recurrent lung cancer.
  • In this study, we evaluated the selected use of FDG-PET for lung cancer patients with re-elevated levels of serum carcinoembryonic antigen (CEA) after curative surgery.
  • METHODS: Among 327 patients who underwent curative resection for primary lung cancer from May 2002 through March 2007, 199 had adenocarcinoma, of whom 78 (39%) had elevated levels of serum CEA before treatment.
  • The sensitivity, specificity, positive predictive value, and negative predictive value of PET in detecting recurrent lung cancer were determined.
  • The selected use of FDG-PET for patients with re-elevated serum CEA levels after surgery can be a practical and effective mode of surveillance for detecting recurrent lung cancer.
  • [MeSH-major] Carcinoembryonic Antigen / blood. Fluorodeoxyglucose F18. Lung Neoplasms / diagnostic imaging. Neoplasm Recurrence, Local / diagnostic imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adenocarcinoma / diagnostic imaging. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pneumologie. 2000 Feb;54(2):49-53 [10731756.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):355S-367S [17873180.001]
  • [Cites] J Nucl Med. 1995 May;36(5):788-93 [7738649.001]
  • [Cites] Cancer. 1986 Jun 15;57(12):2389-96 [3697937.001]
  • [Cites] Ann Thorac Surg. 2004 Jul;78(1):216-21 [15223432.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Jan;33(1):13-21 [16151765.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):319-23 [9527052.001]
  • [Cites] J Nucl Med. 2001 Nov;42(11):1605-13 [11696628.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Apr;25(4):520-2 [15037265.001]
  • [Cites] Semin Nucl Med. 2002 Oct;32(4):240-71 [12524650.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):174-9 [12118753.001]
  • [Cites] Radiology. 1994 May;191(2):379-82 [8153309.001]
  • [Cites] J Thorac Cardiovasc Surg. 1995 Jul;110(1):130-9; discussion 139-40 [7609536.001]
  • [Cites] Ann Thorac Surg. 2003 Mar;75(3):973-80 [12645726.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1495-512 [7635795.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):862-9 [11313174.001]
  • [Cites] J Thorac Imaging. 2006 May;21(2):123-36 [16770229.001]
  • (PMID = 19967484.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


46. Spivey KA, Banyard J, Solis LM, Wistuba II, Barletta JA, Gandhi L, Feldman HA, Rodig SJ, Chirieac LR, Zetter BR: Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev; 2010 May;19(5):1362-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer.
  • The purpose of this study was to determine the protein expression of collagen XXIII in tumor tissues from a variety of cancers and to assess the utility of collagen XXIII as a biomarker for non-small cell lung cancer (NSCLC).
  • Subsequently, collagen XXIII expression was analyzed in three separate cohorts using tissue microarrays with representative tumor and control lung tissues from NSCLC patients.
  • Within lung cancer tissues, collagen XXIII staining was enriched in NSCLC subtypes.
  • Collagen XXIII was present in 294 of 333 (88%) lung adenocarcinomas and 97 of 133 (73%) squamous cell carcinomas.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AACR
  • [Cites] Ann Intern Med. 2004 May 4;140(9):740-53 [15126259.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20989-94 [12644459.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5361-6 [15328173.001]
  • [Cites] Br J Cancer. 1997;75(10):1509-14 [9166946.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1395-9 [9537238.001]
  • [Cites] Lancet. 1999 Jun 5;353(9168):1930-3 [10371572.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):257-62 [16231326.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(13):1724-30; discussion 1730-1 [16425524.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):21546-57 [16728390.001]
  • [Cites] Oncology. 2006;70(3):203-11 [16809939.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):87-94 [16876904.001]
  • [Cites] Ai Zheng. 2006 Nov;25(11):1361-7 [17094902.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):169-81 [17318210.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2634-42 [17473194.001]
  • [Cites] Curr Opin Pulm Med. 2007 Jul;13(4):284-9 [17534174.001]
  • [Cites] J Biol Chem. 2007 Sep 14;282(37):27424-35 [17627939.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):1S-19S [17873156.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Biomed Pharmacother. 2007 Oct;61(9):515-9 [17913444.001]
  • [Cites] Annu Rev Pathol. 2006;1:331-48 [18039118.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5578-83 [18065730.001]
  • [Cites] Histol Histopathol. 2008 Jun;23(6):693-700 [18366007.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):548-52 [18385728.001]
  • [Cites] Lancet Oncol. 2008 Jul;9(7):676-82 [18598932.001]
  • [Cites] Lung Cancer. 2009 Feb;63(2):164-8 [18599152.001]
  • [Cites] Diagn Cytopathol. 2009 Mar;37(3):178-83 [19170169.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2990-5 [19318550.001]
  • [Cites] Proc Am Thorac Soc. 2009 Apr 15;6(2):201-5 [19349489.001]
  • [Cites] Mod Pathol. 2009 Aug;22(8):1032-43 [19430419.001]
  • [Cites] Carcinogenesis. 2009 Nov;30(11):1903-9 [19736307.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8B):1977-86 [19040416.001]
  • [Cites] Cancer. 2000 Dec 1;89(11 Suppl):2468-73 [11147629.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):823-30 [11764070.001]
  • [Cites] EMBO J. 2002 Apr 2;21(7):1524-34 [11927537.001]
  • [Cites] Acta Odontol Latinoam. 2002;15(1-2):29-37 [15208940.001]
  • (PMID = 20447926.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA090578; United States / NCI NIH HHS / CA / R01 CA092824; United States / NCI NIH HHS / CA / CA070907-129004; United States / NCI NIH HHS / CA / P20 CA090578-05; United States / NCI NIH HHS / CA / CA092824; United States / NCI NIH HHS / CA / R01 CA074386; United States / NCI NIH HHS / CA / P50CA70907; United States / NCI NIH HHS / CA / R01 CA092824-07; United States / NCI NIH HHS / CA / CA074386; United States / NCI NIH HHS / CA / CA90578; United States / NCI NIH HHS / CA / P50 CA070907-129004; United States / NCI NIH HHS / CA / P50 CA090578; United States / NCI NIH HHS / CA / CA090578-05; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / CA092824-07; United States / NCI NIH HHS / CA / R01 CA074386-11
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / COL23A1 protein, human; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ NIHMS186813; NLM/ PMC2880394
  •  go-up   go-down


47. Tani M, Kawai M, Miyazawa M, Hirono S, Ina S, Nishioka R, Fujita Y, Uchiyama K, Yamaue H: Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma. Langenbecks Arch Surg; 2009 Mar;394(2):249-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma.
  • BACKGROUND: Prognosis of the patients with pancreatic adenocarcinoma is still poor due to a recurrence, and liver metastasis is a distant metastasis that is foreboded the short survival period.
  • METHODS: Between 1999 and 2005, 68 patients for pancreatic adenocarcinoma underwent a pancreaticoduodenectomy (n = 17), a pylorus-preserving pancreaticoduodenectomy (n = 27), distal pancreatectomy (n = 22), or total pancreatectomy (n = 2) with an extensive lymph node dissection.
  • RESULTS: A tumor recurrence occurred to 55 patients (13 of the liver, 21 of the local recurrence, 16 of peritoneal dissemination, three of the lymph node, and two of lung).
  • The median survival time (MST) was 13.6 months, and MST of patients with a liver metastasis as an initial recurrent site was 13.7 months; the liver metastasis as an initial recurrent site has no impact on the MST after pancreatic resection.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymph Node Excision / methods. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1 [17114007.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Pancreatology. 2002;2(2):79-88 [12123098.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Pancreas. 2002 Nov;25(4):366-72 [12409831.001]
  • [Cites] J Gastrointest Surg. 2006 Apr;10(4):511-8 [16627216.001]
  • [Cites] Surgery. 2004 Nov;136(5):1003-11 [15523393.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Br J Surg. 1997 Oct;84(10 ):1370-6 [9361591.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):56-61 [2354408.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] Ann Surg. 1999 May;229(5):613-22; discussion 622-4 [10235519.001]
  • [Cites] Am J Surg. 1994 Oct;168(4):361-4 [7943597.001]
  • [Cites] World J Surg. 1999 Sep;23(9):888-91 [10449815.001]
  • [Cites] Ann Surg Oncol. 2004 Mar;11(3):304-9 [14993026.001]
  • [Cites] J Surg Oncol. 2006 May 1;93(6):485-90 [16615151.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Eur J Cancer. 1991;27(10 ):1258-63 [1835595.001]
  • [Cites] Cancer. 1993 Oct 1;72 (7):2118-23 [8104092.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Gut. 2005 Mar;54(3):385-7 [15710987.001]
  • [Cites] J Am Coll Surg. 2004 May;198(5):722-31 [15110805.001]
  • [Cites] Surgery. 1997 Sep;122(3):553-66 [9308613.001]
  • [Cites] J Am Coll Surg. 2006 Sep;203(3):345-52 [16931307.001]
  • [Cites] World J Surg. 1999 Sep;23(9):946-9 [10449825.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):1-7 [16794381.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] World J Surg. 1997 Feb;21(2):195-200 [8995078.001]
  • (PMID = 18343944.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


48. Shitara K, Munakata M, Ishiguro A, Okada R, Tomioka R, Mitobe S, Sakata Y: [A case of recurrent breast cancer complicated with pericardial effusions and cardiac tamponade]. Gan To Kagaku Ryoho; 2006 Jul;33(7):961-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent breast cancer complicated with pericardial effusions and cardiac tamponade].
  • After one year left lung metastasis and malignant pleural effusion had resisted and progressed against several types of chemotherapy.
  • The adenocarcinoma was detected from effusion.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835487.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 905Z5W3GKH / Thiotepa
  •  go-up   go-down


49. Ludwick C, Gilks CB, Miller D, Yaziji H, Clement PB: Aggressive behavior of stage I ovarian mucinous tumors lacking extensive infiltrative invasion: a report of four cases and review of the literature. Int J Gynecol Pathol; 2005 Jul;24(3):205-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On follow-up, each patient experienced recurrent disease 7 months to 4.5 years after diagnosis, including hematogenous spread to lung and/or bone and liver in three patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma in Situ / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968194.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


50. Ohta Y, Shimizu Y, Matsumoto I, Tamura M, Oda M, Watanabe G: Retrospective review of lung cancer patients with pleural dissemination after limited operations combined with parietal pleurectomy. J Surg Oncol; 2005 Sep 15;91(4):237-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective review of lung cancer patients with pleural dissemination after limited operations combined with parietal pleurectomy.
  • BACKGROUND AND OBJECTIVES: The long-term control of malignant effusion is necessary to achieve long-term survival in lung cancer patients with carcinomatous pleuritis.
  • RESULTS: Adenocarcinoma was the dominant histology, and the pathological stages were IIIB in 34 cases and IV (intrapulmonary metastasis) in 8 cases.
  • Among the 24 patients whose recurrent patterns could be identified, only 2 patients developed recurrent malignant effusion.
  • [MeSH-major] Lung Neoplasms / pathology. Lung Neoplasms / surgery. Pleura / surgery. Pleural Effusion / etiology. Pleural Effusion / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16121347.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Job B, Bernheim A, Beau-Faller M, Camilleri-Broët S, Girard P, Hofman P, Mazières J, Toujani S, Lacroix L, Laffaire J, Dessen P, Fouret P, LG Investigators: Genomic aberrations in lung adenocarcinoma in never smokers. PLoS One; 2010;5(12):e15145
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic aberrations in lung adenocarcinoma in never smokers.
  • BACKGROUND: Lung cancer in never smokers would rank as the seventh most common cause of cancer death worldwide.
  • METHODS AND FINDINGS: We performed high-resolution array comparative genomic hybridization analysis of lung adenocarcinoma in sixty never smokers and identified fourteen new minimal common regions (MCR) of gain or loss, of which five contained a single gene (MOCS2, NSUN3, KHDRBS2, SNTG1 and ST18).
  • NSD1 and FUS are oncogenes hitherto not known to be associated with lung cancer.
  • SNP array analysis validated copy-number aberrations and revealed that RB1 and WRN were altered by recurrent copy-neutral loss of heterozygosity.
  • Multiple genetic pathways defined by gains of MYC, deletions of RB1 and WRN or gains on 7p and 7q are involved in lung adenocarcinoma in never smokers.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Genomics. Lung Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1309-13 [11245426.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5561-70 [15994928.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4464-8 [12154056.001]
  • [Cites] Oncogene. 2002 Oct 7;21(45):6877-83 [12362270.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1263-70 [12599234.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Nature. 1983 Oct 27-Nov 2;305(5937):779-84 [6633649.001]
  • [Cites] Stat Med. 1990 Jul;9(7):811-8 [2218183.001]
  • [Cites] Science. 1996 Oct 18;274(5286):430-2 [8832894.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):721-9 [9989822.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30 [15983384.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] Genome Res. 2006 Sep;16(9):1149-58 [16899652.001]
  • [Cites] Genome Res. 2006 Sep;16(9):1136-48 [16899659.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):469-71 [17290053.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):472-8 [17290054.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):561-70 [17290066.001]
  • [Cites] J Clin Pathol. 2007 Apr;60(4):337-40 [16916998.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Apr 1;182(1):1-11 [18328944.001]
  • [Cites] Clin Cancer Res. 2008 Sep 15;14(18):5731-4 [18794081.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] Nat Rev Cancer. 2009 Mar;9(3):216-24 [19212324.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5312-7 [19279207.001]
  • [Cites] Nature. 2009 Jun 25;459(7250):1085-90 [19553991.001]
  • [Cites] Nucleic Acids Res. 2009 Jul;37(13):4181-93 [19570852.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):947-57 [19692680.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):958-67 [19692684.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4232-5 [19667260.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4247-53 [19667264.001]
  • [Cites] Clin Cancer Res. 2009 Sep 15;15(18):5622-5 [19755390.001]
  • [Cites] Clin Cancer Res. 2009 Sep 15;15(18):5646-61 [19755392.001]
  • [Cites] J Mol Cell Biol. 2009 Dec;1(2):82-92 [19783543.001]
  • [Cites] Nature. 2010 Jan 14;463(7278):184-90 [20016488.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4806-12 [15870700.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8235-42 [16322280.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1556-64 [16187286.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1371-5 [16452191.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1647-53 [16533793.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1700-4 [16505411.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8822-7 [16723399.001]
  • [Cites] Bioinformatics. 2006 Jun 15;22(12):1540-2 [16595560.001]
  • [Cites] Oncogene. 2004 Dec 9;23(57):9295-302 [15489893.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1642-6 [15753357.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • (PMID = 21151896.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2997777
  • [Investigator] Dartevelle P; Dulmet E; Leroy-Ladurie F; de Montpreville V; Monnet I; Bernard A; Piard F; Alifano M; Camilleri-Broët S; Régnard JF; Hofman P; Hofman V; Mouroux J; Trédaniel J; Beau-Faller M; Massard G; Neuville A; Antoine M; Cadranel J; Brouchet L; Mazières J; Rouquette I; Saint-Blancard P; Vaylet F; Berhneim A; Dessen P; Dufour F; Dorvault N; Fouret P; Job B; Lacroix L; Lazar V; Richon C; Roux V; Saulnier P; Taranchon E; Toujani S; Valent A; Girard P; Gossot D; Validire P; Laffaire J
  •  go-up   go-down


52. Yamada T, Ohtsubo K, Mouri H, Yamashita K, Yasumoto K, Izumi K, Zen Y, Watanabe H, Yano S: Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis. Int J Clin Oncol; 2009 Oct;14(5):468-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a 65-year-old man with recurrent prostate cancer who presented with meningeal carcinomatosis.
  • In September 2007, he had been diagnosed with mixed type small cell carcinoma and adenocarcinoma at clinical stage T4N1M1 (primary prostate tumor with multiple bone, liver, and lymph node metastases) and hormonal therapy had been administered.
  • A different chemotherapy regimen was then administered, consisting of a combination of carboplatin plus irinotecan, which is one of the most common first-line treatments for extensive-stage small cell lung carcinoma.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2002 Sep;37(3):319-23 [12234702.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):804-7 [1311395.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3072-80 [12118020.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):333-8 [12781433.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2122-6 [11391593.001]
  • [Cites] Neuro Oncol. 2009 Feb;11(1):80-91 [18784279.001]
  • [Cites] Br J Cancer. 2007 Jul 16;97(2):162-9 [17579629.001]
  • [Cites] Int J Urol. 2006 Sep;13(9):1254-8 [16984566.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3281-4 [18591564.001]
  • [Cites] Urology. 1992 May;39(5):411-6 [1315995.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2728-30 [6722732.001]
  • [Cites] Urol Oncol. 2006 Jul-Aug;24(4):313-7 [16818183.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):935-7 [1311396.001]
  • [Cites] J Clin Oncol. 1986 Nov;4(11):1620-7 [3021922.001]
  • [Cites] Mol Interv. 2003 Mar;3(2):90-105, 51 [14993430.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1168-71 [18309954.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):365-70 [17011068.001]
  • [Cites] Int J Clin Oncol. 2008 Apr;13(2):169-72 [18463964.001]
  • [Cites] Biol Pharm Bull. 1999 Apr;22(4):428-31 [10328568.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):733-9 [9477107.001]
  • [Cites] Clin Lung Cancer. 2008 Jan;9(1):35-8 [18282356.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9209-16 [15604294.001]
  • (PMID = 19856060.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptide Fragments; 0 / Recombinant Proteins; 0 / pro-gastrin-releasing peptide (31-98); 0H43101T0J / irinotecan; BG3F62OND5 / Carboplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


53. Navi BB, DeAngelis LM, Segal AZ: Multifocal strokes as the presentation of occult lung cancer. J Neurooncol; 2007 Dec;85(3):307-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal strokes as the presentation of occult lung cancer.
  • These atypical features prompted a malignancy evaluation which revealed an occult lung adenocarcinoma.
  • Our patient had a rapidly deteriorating course with recurrent strokes despite numerous anti-platelet and anti-coagulant agents, and was only responsive to chemotherapy aimed at the underlying cancer.
  • [MeSH-major] Adenocarcinoma / complications. Infarction, Middle Cerebral Artery / etiology. Lung Neoplasms / complications. Stroke / etiology. Thrombophilia / complications

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] An Med Interna. 2004 Oct;21(10):495-7 [15511201.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):267-9 [15735915.001]
  • [Cites] Neurology. 2004 Jun 8;62(11):2025-30 [15184609.001]
  • [Cites] Arch Neurol. 1976 Apr;33(4):260-4 [1259640.001]
  • [Cites] Am J Med. 1987 Oct;83(4):746-56 [3674060.001]
  • [Cites] Schweiz Arch Neurol Psychiatr (1985). 1988;139(2):5-11 [2455936.001]
  • [Cites] Medicine (Baltimore). 1985 Jan;64(1):16-35 [3965856.001]
  • (PMID = 17611718.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


54. Asano M, Matsuo K, Ueda Y, Tsushima M, Mizuta M, Fujiwara K, Yonei T, Sato T: [Pulmonary carcinomatous lymphangiosis from recurrent breast cancer 10 years after resection of the primary tumor]. Nihon Kokyuki Gakkai Zasshi; 2009 Jul;47(7):602-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary carcinomatous lymphangiosis from recurrent breast cancer 10 years after resection of the primary tumor].
  • The specimen of transbronchial lung biopsy showed undifferentiated adenocarcinoma cells in lymphatics identified by lymphatic endothelium antibody D2-40 stain, so we diagnosed carcinomatous lymphangiosis.
  • We must keep in mind that some cancers relapse after a long disease-free interval.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Breast Neoplasms / pathology. Lung Neoplasms / secondary. Lymphatic System / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19637802.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


55. Shitara K, Munakata M, Ishiguro A, Kudo T, Okada R, Tomioka R, Mitobe S, Yokoyama S, Sakata Y: [Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma]. Gan To Kagaku Ryoho; 2006 Oct;33(10):1497-1500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma].
  • CASE REPORT: A 53-year-old woman was treated with combination chemotherapy of irinotecan plus cisplatin for a recurrent ovarian clear cell adenocarcinoma.
  • Emergency laparotomy was not performed because of poor performance status with multiple lung metastases, pleural effusion and pericardial effusion.
  • Colonoscopy showed a perforated wall at the cecum, and a long tube with balloon was inserted for occlusion.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cecal Diseases / etiology. Intestinal Perforation / etiology. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Colonoscopy. Drainage. Drug Administration Schedule. Fatal Outcome. Female. Humans. Lung Neoplasms / secondary. Middle Aged. Pleural Effusion, Malignant / etiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033246.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


56. Kasai T, Kishi K, Kawabata M, Narui K, Momomura S, Yoshimura K: Cardiac metastasis from lung adenocarcinoma causing atrioventricular block and left ventricular outflow tract obstruction. Chest; 2007 May;131(5):1569-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac metastasis from lung adenocarcinoma causing atrioventricular block and left ventricular outflow tract obstruction.
  • Cardiac metastasis from lung cancer is rarely diagnosed antemortem, as it usually causes no symptoms or signs.
  • We report the case of a 56-year-old man with recurrent lung adenocarcinoma in whom developed a large mass in the ventricular septum, complete atrioventricular block, and obstruction of the left ventricular outflow tract.
  • [MeSH-major] Adenocarcinoma / secondary. Heart Block / etiology. Heart Neoplasms / secondary. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17494807.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Tajiri M, Kameda Y, Nakayama H, Sakamoto K: Prognosis and morphometrical features of non-bronchioloalveolar cell adenocarcinoma: an assessment of the non-alveolar replacing area and high grade atypical area. J Clin Pathol; 2006 Mar;59(3):269-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis and morphometrical features of non-bronchioloalveolar cell adenocarcinoma: an assessment of the non-alveolar replacing area and high grade atypical area.
  • AIM: It has become obvious that the prognosis of bronchioloalveolar cell carcinoma (BAC) in small peripheral adenocarcinoma of the lung is good, but most cases actually treated as pulmonary adenocarcinoma in hospitals tend to be non-bronchioloalveolar cell carcinoma (non-BAC).
  • RESULTS: The NAAR and HAAR were significantly higher in the recurrent cases than in the recurrence free cases.
  • [MeSH-major] Adenocarcinoma / pathology. Bronchial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 1999 Dec;68(6):2069-73 [10616979.001]
  • [Cites] Ann Thorac Surg. 2000 Mar;69(3):893-7 [10750779.001]
  • [Cites] Lung Cancer. 2000 Sep;29(3):179-88 [10996420.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7950-4 [11691817.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):937-51 [12826886.001]
  • [Cites] Am J Clin Pathol. 1999 May;111(5):610-22 [10230351.001]
  • [Cites] Anal Quant Cytol. 1982 Sep;4(3):225-32 [7149488.001]
  • [Cites] Mod Pathol. 1990 May;3(3):314-20 [2362938.001]
  • [Cites] Am J Surg Pathol. 1990 Oct;14(10):904-12 [2403196.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Am J Surg Pathol. 1996 May;20(5):553-62 [8619420.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):198-206 [15043309.001]
  • (PMID = 16505277.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860342
  •  go-up   go-down


58. Barajas RF, Chang JS, Sneed PK, Segal MR, McDermott MW, Cha S: Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol; 2009 Feb;30(2):367-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
  • The purpose of our study was to determine whether relative cerebral blood volume (rCBV), relative peak height (rPH), and percentage of signal-intensity recovery (PSR) derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging can distinguish recurrent metastatic tumor from radiation necrosis.
  • Subsequent surgical resection or clinicoradiologic follow-up established a diagnosis of recurrent metastatic tumor or radiation necrosis.
  • RESULTS: The mean, minimum, and maximum PSR values were significantly lower (P < .01) in cases of recurrent metastatic tumor.
  • The mean and maximum rCBV and rPH values were significantly higher (P < .02) in the recurrent metastatic tumor group.
  • CONCLUSIONS: The findings of our study suggest that perfusion MR imaging may be used to differentiate recurrent intra-axial metastatic tumor from gamma knife-induced radiation necrosis.
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Breast Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Contrast Media. Diagnosis, Differential. Female. Humans. Kidney Neoplasms / pathology. Male. Middle Aged. Necrosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19022867.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS045013; United States / NCRR NIH HHS / RR / TL1 RR024129-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


59. Murakami S, Yokose T, Saito H, Sakuma Y, Matsukuma S, Hasegawa C, Kondo T, Oshita F, Ito H, Tsuboi M, Nakayama H, Kameda Y, Noda K, Yamada K: Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course. Lung Cancer; 2010 Sep;69(3):361-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course.
  • The fusion gene EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) was recently identified as a novel genetic alteration in non-small-cell lung cancer.
  • The clinicopathological features of EML4-ALK-positive adenocarcinoma are reported to include its high incidence in young, non-smoking patients, tumors that show distinct solid or acinar growth patterns with or without signet-ring cell histology, and its mutually exclusive occurrence with mutations in EGFR and KRAS.
  • Here, we report a case of EML4-ALK-positive lung adenocarcinoma that showed multiple metachronous lesions on the pleura and pulmonary field, suspected to be a recurrence of lung adenocarcinoma after a 20-year disease-free interval.
  • The slow clinical course may be characteristic of EML4-ALK-positive lung adenocarcinoma.
  • Therefore, long-term observation of patients with EML4-ALK-positive lung adenocarcinomas is required after surgery.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Pleural Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20659620.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / EML4-ALK fusion protein, human; 0 / KRAS protein, human; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


60. Kawashima O, Ibe T, Kakegawa S, Nakano T, Shimizu K: [Surgical treatment and outcome for postoperative recurrent or second primary lung cancer]. Kyobu Geka; 2010 Oct;63(11):935-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment and outcome for postoperative recurrent or second primary lung cancer].
  • From 2000 to 2009, we retrospectively reviewed 62 patients who underwent surgical treatment for postoperative recurrent or 2nd primary lung cancer.
  • The histology of the initial primary lung cancer was adenocarcinoma in 42 patients, squamous cell carcinoma in 18, large cell carcinoma in 1 and small cell carcinoma in 1.
  • The surgical procedures for 1st operation were lobectomy with mediastinal lymph node dissection in 52, bilobectomy with mediastinal lymph node dissection in 4, sleeve lobectomy with mediastinal lymph node dissection in 3, and lobectomy + segmentectomy or wedge resection with mediastinal lymph node dissection in 3. p-stage of the 1st primary lung cancer was IA in 22, IB in 16, II A in 7, IIB in 6, IIIA in 6, IIIB in 4, and IV in 1.
  • Of these, 42 patients were diagnosed 2nd primary lung cancer, 20 patients were recurrent disease histologically.
  • The 5-year survival rate of the patients with metachronous and recurrent disease from the 2nd operation was 54.1%, and 43.1%, respectively.
  • Although lobectomy or CP should be considered the surgical procedure of choice for patients with metachronous lung cancer, with this result, we consider that postoperative good survival can be expected by even the limited operation for cases of postoperative recurrent or 2nd primary lung cancer because of possible early detection.
  • We conclude that limited surgery may be a treatment of choice for recurrent or 2nd primary lung cancer after initial operation.
  • [MeSH-major] Lung Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20954346.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


61. Lee NS, Park HS, Won JH, Hong DS, Uh ST, Lee SJ, Kim JH, Kim SK, Ahn MJ, Choi JH, Yang SC, Lee JA, Lee KS, Yim CY, Lee YC, Kim CS, Lee MH, Jung KD, Moon H, Lee YS: Randomized, multi-center phase II trial of docetaxel plus cisplatin versus etoposide plus cisplatin as the first-line therapy for patients with advanced non-small cell lung cancer. Cancer Res Treat; 2005 Dec;37(6):332-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized, multi-center phase II trial of docetaxel plus cisplatin versus etoposide plus cisplatin as the first-line therapy for patients with advanced non-small cell lung cancer.
  • PURPOSE: We prospectively conducted a multi-center, open-label, randomized phase II trial to compare the efficacy and safety of docetaxel plus cisplatin (DC) and etoposide plus cisplatin (EC) for treating advanced stage non-small cell lung cancer (NSCLC).
  • MATERIALS AND METHODS: Seventy-eight previously untreated patients with locally advanced, recurrent or metastatic NSCLC were enrolled in this study.
  • The prognostic factors for longer survival were an earlier disease stage (stage III, p=0.0095), the responders to DC (p=0.0174) and the adenocarcinoma histology (p=0.0454).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • [Cites] Chest. 1994 Sep;106(3):861-5 [7521815.001]
  • [Cites] Semin Oncol. 1986 Sep;13(3 Suppl 3):104-14 [3020693.001]
  • [Cites] Semin Oncol. 1989 Aug;16(4 Suppl 6):10-21 [2548280.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):331-4 [9602269.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1087-100 [9607565.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3188-94 [10506617.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3210-8 [11432888.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3016-24 [12837811.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):330-53 [14691125.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):254-61 [14722033.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1069-75 [15860487.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1866-72 [8410111.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1948-53 [9586914.001]
  • [Cites] N Engl J Med. 1992 Nov 12;327(20):1434-41 [1328881.001]
  • [Cites] Chest. 1991 Jun;99(6):1326-8 [1645242.001]
  • [Cites] Semin Oncol. 1994 Jun;21(3 Suppl 6):49-59 [8052874.001]
  • [Cites] Lung Cancer. 2002 Dec;38 Suppl 4:5-12 [12480189.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • (PMID = 19956368.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2785933
  • [Keywords] NOTNLM ; Cisplatin / Docetaxel / Etoposide / Non-small-cell lung carcinoma
  •  go-up   go-down


62. Sterlacci W, Fiegl M, Hilbe W, Jamnig H, Oberaigner W, Schmid T, Augustin F, Auberger J, Obermann EC, Tzankov A: Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients. J Thorac Oncol; 2010 Sep;5(9):1325-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients.
  • INTRODUCTION: A large group of interacting molecular factors, involved in epithelial-mesenchymal transition, epidermal growth factor receptor (EGFR) signaling, and G1 mitotic phase, are shown to play an important role in cancerogenesis and progression of non-small cell lung cancer (NSCLC).
  • In analogy to EGFR, recurrent numeric gene aberrations, particularly high-level amplifications, of cyclin D1 were obvious.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Cyclin D1 / metabolism. Cyclin D3 / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Lung Neoplasms / metabolism. Mitosis / physiology
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cyclin-Dependent Kinase Inhibitor p27. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Tissue Array Analysis. Young Adult


63. Melosky B, Agulnik J, Assi H: Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib. Curr Oncol; 2008 Dec;15(6):279-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib.
  • BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIS) and chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung cancer (NSCLC) following failure of first-line platinum-based chemotherapy.
  • Although the 3 available therapeutic agents-docetaxel, erlotinib, and pemetrexed-have significantly changed the treatment landscape for recurrent NSCLC, the optimal selection of second- and third-line therapy has not been established.
  • This practice review examines the outcomes in clinical practice of using second-line erlotinib followed by third-line chemotherapy in the treatment of recurrent metastatic NSCLC.
  • Patients with recurrent nsclc who had received second-line erlotinib therapy followed by third-line chemotherapy were selected by census.
  • Subgroup analysis showed that all patient subgroups demonstrated benefit from second-line erlotinib treatment; improved benefit was observed in patients who developed rash, in female patients, in never smokers, in Asian patients, in patients with positive EGFR status, and in patients with adenocarcinoma histology.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2008 Aug;61(2):262-5 [18358559.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] Oncologist. 2008;13 Suppl 1:28-36 [18263772.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3913-21 [17606725.001]
  • [Cites] Oncologist. 2007 May;12(5):610-21 [17522250.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1545-52 [17442998.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6049-55 [17062680.001]
  • [Cites] Clin Lung Cancer. 2006 May;7(6):389-94 [16800964.001]
  • [Cites] Clin Lung Cancer. 2006 May;7(6):385-8 [16800963.001]
  • [Cites] Oncologist. 2006 Jun;11(6):655-65 [16794244.001]
  • [Cites] Ann Oncol. 2006 Mar;17 Suppl 2:ii46-48 [16608981.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5856-8 [16043825.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805 [15701870.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3238-47 [15310767.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):785-94 [14990633.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):777-84 [14990632.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5813-24 [14676101.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2354-62 [10856094.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 May;66(2):155-62 [18083041.001]
  • (PMID = 19079629.001).
  • [ISSN] 1198-0052
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2601023
  • [Keywords] NOTNLM ; Non-small-cell lung cancer / egfr / epidermal growth factor receptor / erlotinib / nsclc / retrospective practice review / second-line / tki / tyrosine kinase inhibitor
  •  go-up   go-down


64. Socinski MA, Scappaticci FA, Samant M, Kolb MM, Kozloff MF: Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol; 2010 Mar;5(3):354-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
  • INTRODUCTION: Bevacizumab (B) improves survival of patients with metastatic, nonsquamous non-small cell lung cancer.
  • Based on encouraging results from preclinical studies combining B with sunitinib (S), a phase II, randomized, open-label study (Study Assessing the Blockade of both VEGF Receptor and ligand to enhance Efficacy in Lung) was initiated to assess clinical outcomes of adding S to paclitaxel (P)/carboplatin (C) + B (PCB) for first-line treatment of locally advanced, metastatic, or recurrent nonsquamous non-small cell lung cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032789.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; 2S9ZZM9Q9V / Bevacizumab; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


65. Brahmania M, Kanthan CS, Kanthan R: Collision tumor of the colon--colonic adenocarcinoma and ovarian granulosa cell tumor. World J Surg Oncol; 2007;5:118
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of the colon--colonic adenocarcinoma and ovarian granulosa cell tumor.
  • We report the first case, to our knowledge in the English literature, of a collision tumor composed of a colonic adenocarcinoma arising in a sigmoid diverticulum coexisting with a recurrent ovarian granulosa cell tumor.
  • Surgical removal of the mass and pathological examination revealed the presence of a colonic adenocarcinoma arising in a large sigmoid diverticulum coexistent with a second neoplastic tumor phenotype; confirmed to be a delayed recurrent ovarian granulosa cell tumor.
  • She developed lung metastases from the recurrent ovarian tumor within 6 months and died within a year of follow-up.
  • This is the first case reported of a collision tumor composed of adenocarcinoma colon and recurrent granulosa cell tumor representing an example of two independent tumors in a unique one-on-another collision.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colonic Neoplasms / diagnosis. Granulosa Cell Tumor / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ceska Gynekol. 2000 May;65(3):163-6 [10953492.001]
  • [Cites] Rom J Morphol Embryol. 2007;48(1):75-8 [17502956.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1180-9 [12637488.001]
  • [Cites] Pathol Oncol Res. 2003;9(3):188-92 [14530814.001]
  • [Cites] Cancer. 1976 Jul;38(1):335-40 [181131.001]
  • [Cites] Dis Colon Rectum. 1984 Dec;27(12):822-4 [6389052.001]
  • [Cites] Gastroenterol Clin Biol. 1990;14(2):185-6 [2328885.001]
  • [Cites] Surgery. 1993 Feb;113(2):223-6 [8430371.001]
  • [Cites] J Surg Oncol. 1994 Feb;55(2):71-7 [8121188.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):484-8 [8774662.001]
  • [Cites] Pathol Int. 1996 Jul;46(7):538-9 [8870012.001]
  • [Cites] Indian J Gastroenterol. 1997 Jan;16(1):28-9 [9167378.001]
  • [Cites] Arch Pathol Lab Med. 1998 Mar;122(3):262-5 [9823866.001]
  • [Cites] Surg Oncol. 2005 Jul;14(1):11-25 [15777886.001]
  • [Cites] Dig Dis Sci. 2002 Dec;47(12):2758-9 [12498297.001]
  • (PMID = 17949502.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2164962
  •  go-up   go-down


66. Mohamed MK, Ramalingam S, Lin Y, Gooding W, Belani CP: Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol; 2005 May;16(5):780-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.
  • BACKGROUND: Gefitinib (Iressa) is active as a single agent in the treatment of select patients with recurrent non-small cell lung cancer (NSCLC).
  • Baseline patient characteristics were: median age, 69 years; males, 57%; adenocarcinoma, 56%.
  • CONCLUSIONS: Occurrence of skin rash and baseline PS of 0/1 were associated with improved survival with gefitinib for recurrent NSCLC patients at our institution.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15728108.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


67. Kakeya H, Inoue Y, Sawai T, Ikuta Y, Ohno H, Yanagihara K, Higashiyama Y, Miyazaki Y, Soda H, Tashiro T, Kohno S: [A case of brain metastasis discovered after surgery for lung cancer based on changes in CEA, in which long-term survival was obtained by repeated gammaknife irradiation]. Nihon Kokyuki Gakkai Zasshi; 2005 Dec;43(12):736-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of brain metastasis discovered after surgery for lung cancer based on changes in CEA, in which long-term survival was obtained by repeated gammaknife irradiation].
  • A 58-year-old man underwent right lower lobectomy for lung adenocarcinoma in June 1998.
  • Long-term survival was possible by repeated gammaknife irradiation for brain metastases.
  • Monitoring of CEA played an important role in finding recurrent brain metastasis in this patient.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Radiosurgery
  • [MeSH-minor] Carcinoembryonic Antigen / blood. Humans. Lung Neoplasms / surgery. Male. Middle Aged. Pneumonectomy. Reoperation. Survivors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16457335.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


68. Poltinnikov IM, Fallon K, Xiao Y, Reiff JE, Curran WJ Jr, Werner-Wasik M: Combination of longitudinal and circumferential three-dimensional esophageal dose distribution predicts acute esophagitis in hypofractionated reirradiation of patients with non-small-cell lung cancer treated in stereotactic body frame. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):652-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of longitudinal and circumferential three-dimensional esophageal dose distribution predicts acute esophagitis in hypofractionated reirradiation of patients with non-small-cell lung cancer treated in stereotactic body frame.
  • PURPOSE: To evaluate dosimetric predictors of acute esophagitis (AE) and clinical outcome of patients with non-small-cell lung cancer (NSCLC) receiving reirradiation.
  • METHODS AND MATERIALS: Seventeen patients with NSCLC received reirradiation to the lung tumors/mediastinum, while immobilized in stereotactic body frame (SBF).
  • CONCLUSIONS: Reirradiation using hypofractionated three-dimensional radiotherapy and SBF immobilization is an effective strategy for palliation of symptoms in selected patients with recurrent NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Esophagitis / etiology. Esophagus / radiation effects. Lung Neoplasms / radiotherapy. Radiation Injuries / complications
  • [MeSH-minor] Acute Disease. Adenocarcinoma / radiotherapy. Aged. Carcinoma, Squamous Cell / radiotherapy. Female. Humans. Immobilization / instrumentation. Immobilization / methods. Male. Mediastinal Neoplasms / radiotherapy. Middle Aged. Radiotherapy Dosage. Radiotherapy, Conformal. Retreatment. Stereotaxic Techniques / instrumentation


69. Chen YJ, Chang GC, Chen WH, Hsu HC, Lee TS: Local metastases along the tract of needle: a rare complication of vertebroplasty in treating spinal metastases. Spine (Phila Pa 1976); 2007 Oct 1;32(21):E615-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We report local metastases along the needle tract as a rare complication of percutaneous vertebroplasty in treating spinal metastases in a lung cancer patient.
  • METHODS: A 76-year-old man diagnosed with adenocarcinoma of lung underwent percutaneous vertebroplasty at L1 and L3 vertebral levels due to painful spinal metastases.
  • His condition worsened 3 months later, however, with recurrent back pain and weakness of both legs.
  • [MeSH-minor] Aged. Humans. Lumbar Vertebrae / radiography. Lumbar Vertebrae / surgery. Lung Neoplasms / radiography. Lung Neoplasms / surgery. Male

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906564.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Godoy T C, Vega S J, Rivera G L: [Recurrent left lung atelectasis caused by an endobronchial metastasis of a colon cancer: report of one case]. Rev Med Chil; 2008 Feb;136(2):217-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent left lung atelectasis caused by an endobronchial metastasis of a colon cancer: report of one case].
  • [Transliterated title] Atelectasia pulmonar recurrente secundaria a una metástasis endobronquial de un carcinoma de colon: Caso clínico.
  • We report an 83 year-old woman with a history of a left hemicolectomy due to tubular colon adenocarcinoma, three years ago.
  • Chest X ray examination showed a complete opacity of the left lung.
  • She was treated as a pneumonia and her left lung expanded again.
  • Three weeks later, left lung atelectasis relapsed.
  • A bronchial biopsy showed a moderately differentiated adenocarcinoma, compatible with colon adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Bronchial Neoplasms / secondary. Colonic Neoplasms / pathology. Pulmonary Atelectasis / etiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483676.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


71. Cupisti K, Raffel A, Ramp U, Wolf A, Donner A, Krausch M, Eisenberger CF, Knoefel WT: Synchronous occurrence of a follicular, papillary and medullary thyroid carcinoma in a recurrent goiter. Endocr J; 2005 Apr;52(2):281-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous occurrence of a follicular, papillary and medullary thyroid carcinoma in a recurrent goiter.
  • We report the case of a 52-year-old man with the history of two previous thyroid operations for benign goiters, who developed a recurrent goiter.
  • Postoperative I-131-radioiodine scan showed multiple lung and liver metastases, while calcitonin was negative.
  • (1) he suffered a period of severe staphylococcal sepsis with temporal immunosuppression and (2) he worked for long years as a coremaker in a foundry.
  • This work represented possible long term exposure to inhalative carcinogenous toxins like hydrazine, which caused thyroid parafollicular cell adenomas in an animal model.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Medullary / pathology. Carcinoma, Papillary / pathology. Goiter / complications. Neoplasms, Multiple Primary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Recurrence. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863962.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


72. Okubo K, Yoshioka S, Asukai K, Hata T, Nakanishi M, Maekawa T, Hama N, Kashiwazaki M, Taniguchi M, Tsujie M, Konishi M, Yano K, Fujimoto T: [A case report of primary adenocarcinoma of small intestine]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2792-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of primary adenocarcinoma of small intestine].
  • This is an account of a case of primary adenocarcinoma of the small intestine with peritoneal dissemination successfully treated with chemotherapy.
  • Pathological diagnosis of the resected specimen was adenocarcinoma with lymph nodes metastasis.
  • The peritoneal dissemination consisted of metastatic adenocarcinoma from small intestine.
  • But a recurrent lesion at the ovarium was detected 6 months after surgery.
  • For lung metastasis, the combination chemotherapy with mFOLFOX6 + bevacizumab was administered.
  • Primary small intestinal adenocarcinoma is a rare disease, and it is often diagnosed as advanced cancer because of few characteristic symptoms.
  • [MeSH-major] Adenocarcinoma / therapy. Intestinal Neoplasms / therapy

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224715.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Organoplatinum Compounds; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 2S9ZZM9Q9V / Bevacizumab; 5VT6420TIG / Oxonic Acid; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


73. Kunii N, Morita A, Yoshikawa G, Kirino T: Subdural hematoma associated with dural metastasis--case report--. Neurol Med Chir (Tokyo); 2005 Oct;45(10):519-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient had been treated for breast cancer with disseminated bone and lung metastases.
  • This condition is especially associated with dural metastasis from adenocarcinoma (most frequently stomach cancer) and the clinical outcome depends on the general condition of the patient and the status of the coagulation disorders.
  • If the tumors are multiple, as in this case, extreme caution should be paid to recurrent bleeding in the ipsilateral or contralateral side.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / secondary. Dura Mater. Hematoma, Subdural, Intracranial / etiology. Meningeal Neoplasms / complications. Meningeal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247237.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


74. McKeon A, Ahlskog JE, Britton JW, Lennon VA, Pittock SJ: Reversible extralimbic paraneoplastic encephalopathies with large abnormalities on magnetic resonance images. Arch Neurol; 2009 Feb;66(2):268-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patient 1, a woman aged 63 years, experienced hemiparesis with hemianopia 3 years after a diagnosis of adenocarcinoma of the breast.
  • Patient 2, a woman aged 79 years, presented with monoparesis and epilepsia partialis continua, 1 year after a diagnosis of adenocarcinoma of the breast.
  • Patient 3, a man aged 65 years, had paraneoplastic sensory neuronopathy, limbic encephalitis, antineuronal nuclear autoantibody type 1 (ANNA-1), and squamous cell carcinoma of the lung.
  • Subacute onset of aphasia, delirium, worsening seizures, and rising ANNA-1 titers led to a diagnosis of recurrent limited carcinoma.
  • [MeSH-minor] Aged. Biomarkers / analysis. Breast Neoplasms / complications. Carcinoma / complications. Cognition Disorders / drug therapy. Cognition Disorders / immunology. Disease Progression. Female. Humans. Immunotherapy. Lung Neoplasms / complications. Magnetic Resonance Imaging. Male. Middle Aged. Paresis / drug therapy. Paresis / immunology. Seizures / drug therapy. Seizures / immunology. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Neurol. 2009 Jul;66(7):916 [19597101.001]
  • [ErratumIn] Arch Neurol. 2011 Mar;68(3):371. Britton, Jeffrey A [corrected to Britton, Jeffrey W]
  • (PMID = 19204167.001).
  • [ISSN] 1538-3687
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


75. Edkins S, O'Meara S, Parker A, Stevens C, Reis M, Jones S, Greenman C, Davies H, Dalgliesh G, Forbes S, Hunter C, Smith R, Stephens P, Goldstraw P, Nicholson A, Chan TL, Velculescu VE, Yuen ST, Leung SY, Stratton MR, Futreal PA: Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther; 2006 Aug;5(8):928-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent KRAS codon 146 mutations in human colorectal cancer.
  • We report here the identification of recurrent somatic missense mutations at alanine 146, a highly conserved residue in the guanine nucleotide binding domain.
  • Lung adenocarcinomas and large cell carcinomas did not show codon 146 mutations.
  • [MeSH-minor] Adenocarcinoma / genetics. Amino Acid Sequence. Carcinoma, Large Cell / genetics. DNA Mutational Analysis. DNA, Neoplasm / genetics. Hong Kong. Humans. Leukemia, Myeloid, Acute / genetics. Molecular Sequence Data. Neoplasm Staging. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Sequence Homology, Amino Acid. United States

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2002 Sep;13(9):1438-46 [12196370.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Science. 2003 May 9;300(5621):949 [12738854.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Mar;75(3):1334-8 [418410.001]
  • [Cites] Nature. 1982 Nov 11;300(5888):143-9 [6290897.001]
  • [Cites] Nature. 1982 Nov 11;300(5888):149-52 [7133135.001]
  • [Cites] Mol Cell Biol. 1988 Jun;8(6):2472-8 [3043178.001]
  • [Cites] Carcinogenesis. 1988 Nov;9(11):2073-9 [2902939.001]
  • [Cites] Mol Cell Biol. 1990 Jan;10(1):405-8 [2403644.001]
  • [Cites] Virus Genes. 1991 Jan;5(1):75-9 [2017878.001]
  • [Cites] Hum Mutat. 1996;8(3):258-61 [8889585.001]
  • [Cites] Mutat Res. 2004 Nov;567(2-3):447-74 [15572290.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Gut. 2005 Sep;54(9):1283-6 [15843421.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7591-5 [16140923.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):358-62 [16273091.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3992-5 [16618717.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):299-304 [11208819.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):692-6 [11531254.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1299-304 [11701921.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6451-5 [12438234.001]
  • (PMID = 16969076.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA121113; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / R01 CA121113; United States / NCI NIH HHS / CA / CA062924; United Kingdom / Wellcome Trust / / 077012
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2714972; NLM/ UKMS27311
  •  go-up   go-down


76. Takeda A, Kunieda E, Takeda T, Tanaka M, Sanuki N, Fujii H, Shigematsu N, Kubo A: Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys; 2008 Mar 15;70(4):1057-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer.
  • PURPOSE: To retrospectively analyze opacity changes near primary lung cancer tumors irradiated by using hypofractionated stereotactic radiotherapy (HSRT) to determine the presence or absence of tumor recurrence.
  • METHODS AND MATERIALS: After review-board approval for a retrospective study, we examined data from 50 patients treated with curative intent for proven or highly suspected localized peripheral-lung cancer and followed up for at least 12 months.
  • Abnormal opacities that were suspicious for recurrent tumor appeared in 20 patients at a median of 20.7 months (range, 5.9-61.4 months).
  • [MeSH-major] Lung Neoplasms / radiography. Neoplasm Recurrence, Local / radiography. Radiation Pneumonitis / radiography
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / surgery. Diagnosis, Differential. Diagnostic Errors. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiosurgery. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17905527.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


77. Akerley W, Boucher KM, Bentz JS, Arbogast K, Walters T: A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer. J Thorac Oncol; 2009 Feb;4(2):214-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
  • INTRODUCTION: Erlotinib improves survival in patients with advanced non-small cell lung cancer who have been previously treated with systemic chemotherapy.
  • METHODS: Eligibility criteria included stage IIIB/IV or recurrent non-small cell lung cancer, no prior chemotherapy for systemic disease, performance status = 0 to 1, no history of brain metastases, and weight loss less than 10%.
  • Histologies were adenocarcinoma in 22 and squamous cell in six.
  • CONCLUSIONS: Despite a modest response rate, lack of enrichment for never-smokers and absence of conventional chemotherapy in many patients, the median and long-term survivals were comparable with those expected after conventional sequencing of chemotherapy.
  • Erlotinib as initial therapy was well tolerated and warrants randomized evaluation as first-line treatment for advanced lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179899.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


78. Wang Y, Zhang D, Zheng W, Luo J, Bai Y, Lu Z: Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer; 2008 Mar 15;112(6):1325-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
  • BACKGROUND: Aberrant DNA methylation of the CpG islands for cancer-related genes is among the earliest and most frequent alterations in cancer and may be useful for diagnosing cancer or evaluating recurrent disease.
  • The authors determined the frequency of aberrant promoter methylation of 15 genes in 28 resected primary nonsmall cell lung cancers (NSCLCs) and in 12 corresponding nonmalignant lung tissues.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. DNA Methylation. Genes, Tumor Suppressor. Lung Neoplasms / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Apoptosis Regulatory Proteins / genetics. Cadherins / genetics. Calcium-Calmodulin-Dependent Protein Kinases / genetics. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Case-Control Studies. CpG Islands. Cyclin-Dependent Kinase Inhibitor p15 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Death-Associated Protein Kinases. Female. Humans. In Situ Hybridization. Insulin-Like Growth Factor Binding Proteins / genetics. Lung / metabolism. Lung / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Tissue Inhibitor of Metalloproteinase-3 / genetics. Ubiquitin-Protein Ligases / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 18286531.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / CDH17 protein, human; 0 / Cadherins; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / H-cadherin; 0 / Insulin-Like Growth Factor Binding Proteins; 0 / RNA, Messenger; 0 / TIMP3 protein, human; 0 / Tissue Inhibitor of Metalloproteinase-3; 0 / insulin-like growth factor binding protein-related protein 1; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 6.3.2.- / BRAP protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


79. Raz DJ, Kim JY, Jablons DM: Diagnosis and treatment of bronchioloalveolar carcinoma. Curr Opin Pulm Med; 2007 Jul;13(4):290-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Bronchioloalveolar carcinoma accounts for 5% of lung cancers, although histologically mixed bronchioloalveolar carcinoma and adenocarcinoma account for up to 20%.
  • Bronchioloalveolar carcinoma histology is present in a majority of tumors found on lung-cancer screening by computed tomography.
  • We review issues surrounding the diagnosis and treatment of bronchioloalveolar carcinoma, which often differs from other types of lung cancer.
  • RECENT FINDINGS: A spectrum of disease from histologically pure bronchioloalveolar carcinoma to adenocarcinoma exists.
  • SUMMARY: An understanding of recent developments in the diagnosis and treatment of patients with bronchioloalveolar carcinoma histology is important as early detection of lung cancer becomes more common.
  • The use of epidermal growth factor receptor tyrosine kinase inhibitors should currently be limited to patients with advanced or recurrent disease who have failed cytotoxic chemotherapy.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17534175.001).
  • [ISSN] 1070-5287
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093708-03; United States / NCI NIH HHS / CA / R01 CA093708; United States / NCI NIH HHS / CA / R01 CA093708-03
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 65
  •  go-up   go-down


80. Iqbal FR, Sani A, Gendeh BS, Aireen I: Triple primary cancers of the larynx, lung and thyroid presenting in one patient. Med J Malaysia; 2008 Dec;63(5):417-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triple primary cancers of the larynx, lung and thyroid presenting in one patient.
  • Lung malignancies presenting in association with head and neck tumours are well documented while there have been small series of thyroid synchronous cancers presenting with laryngeal lesions in literature.
  • No cases, to our knowledge, have been reported in literature of a single patient with all three laryngeal, lung and thyroid malignancies.
  • We report one such case of a 71-year-old Chinese man who had undergone a total laryngectomy for a recurrent cancer of the larynx only to be found to have tumours of the lung and thyroid in the post-operative period and he eventually died of post-operative complications.
  • We also discuss screening for lung and thyroid malignancies in patients with head and neck squamous cell carcinoma (SCC).
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Papillary / diagnosis. Carcinoma, Squamous Cell / diagnosis. Laryngeal Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Laryngectomy. Lung / pathology. Lung / surgery. Male. Thyroidectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19803306.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


81. Okagawa T, Uchida T, Suyama M: [A case of postoperative recurrent lung cancer with long survival due to gefitinib efficacy]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1841-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of postoperative recurrent lung cancer with long survival due to gefitinib efficacy].
  • A 70-year-old woman underwent a right middle lobectomy and partial resection of right upper lobe for lung cancer.
  • The pathological findings were well-differentiated adenocarcinoma, pT2N0M0, Stage IB.
  • We diagnosed it as a recurrence of the lung cancer.
  • Then, 1 month after beginning gefitinib, her serum CEA level normalized and the recurrent lesion disappeared on chest CT.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030020.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


82. Kuroda H, Mochizuki S, Shimoda M, Chijiiwa M, Kamiya K, Izumi Y, Watanabe M, Horinouchi H, Kawamura M, Kobayashi K, Okada Y: ADAM28 is a serological and histochemical marker for non-small-cell lung cancers. Int J Cancer; 2010 Oct 15;127(8):1844-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ADAM28 is a serological and histochemical marker for non-small-cell lung cancers.
  • ADAM28 (a disintegrin and metalloproteinase 28) is over-expressed in non-small-cell lung cancer (NSCLC) with correlation to cancer cell proliferation, tumor size and lymph node metastasis.
  • The ADAM28 level in the NSCLC tissue was remarkably 36.9-fold higher than that in the non-neoplastic lung tissue (p < 0.001).
  • The level was also significantly higher in the patients with recurrent carcinoma than the control (p < 0.001) and in the patients with lymph node metastasis than those without metastasis (p < 0.001).
  • There was a positive correlation between the ADAM28 level measured by ELISA system and the degree of immunostaining in the lung adenocarcinomas with a size of <or=20 mm in diameter.
  • The adenocarcinoma patients showing the high immunohistochemical reaction exhibited a poorer disease-free survival than those with the lower immunoreactivity (n = 102; p < 0.05).
  • [MeSH-major] ADAM Proteins / blood. Adenocarcinoma / blood. Biomarkers, Tumor / blood. Carcinoma, Large Cell / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Squamous Cell / blood. Lung Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Cancer. 2012 Oct 1;131(7):E1180
  • (PMID = 20112342.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAM28 protein, human
  •  go-up   go-down


83. Broët P, Tan P, Alifano M, Camilleri-Broët S, Richardson S: Finding exclusively deleted or amplified genomic areas in lung adenocarcinomas using a novel chromosomal pattern analysis. BMC Med Genomics; 2009;2:43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Finding exclusively deleted or amplified genomic areas in lung adenocarcinomas using a novel chromosomal pattern analysis.
  • BACKGROUND: Genomic copy number alteration (CNA) that are recurrent across multiple samples often harbor critical genes that can drive either the initiation or the progression of cancer disease.
  • Up to now, most researchers investigating recurrent CNAs consider separately the marginal frequencies for copy gain or loss and select the areas of interest based on arbitrary cut-off thresholds of these frequencies.
  • In this context, a joint analysis of the copy number changes across tumor samples may bring new insights about patterns of recurrent CNAs.
  • METHODS: We propose to identify patterns of recurrent CNAs across tumor samples from high-resolution comparative genomic hybridization microarrays.
  • Clustering is achieved by modeling the copy number state (loss, no-change, gain) as a multinomial distribution with probabilities parameterized through a latent class model leading to nine patterns of recurrent CNAs.
  • We applied this model to a homogeneous series of 65 lung adenocarcinomas.
  • Our results showed that about thirty percent of the genomic clones were classified either as "exclusively" deleted or amplified recurrent CNAs and could be considered as non random chromosomal events.
  • Most of the known oncogenes or tumor suppressor genes associated with lung adenocarcinoma were located within these areas.
  • CONCLUSION: Analyzing jointly deletions and amplifications through our latent class model analysis allows highlighting specific genomic areas with exclusively amplified or deleted recurrent CNAs which are good candidate for harboring oncogenes or tumor suppressor genes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Res. 2006 Sep;16(9):1149-58 [16899652.001]
  • [Cites] Bioinformatics. 2006 Apr 15;22(8):911-8 [16455750.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1556-64 [16187286.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30 [15983384.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):338-41 [15549096.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jul;25(3):195-204 [10379865.001]
  • [Cites] Genomics. 2007 May;89(5):647-53 [17276656.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Neoplasia. 2008 Mar;10(3):298-302 [18320074.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 [18077431.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • (PMID = 19594952.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2718000
  •  go-up   go-down


84. Huang CC, Taylor JM, Beer DG, Kardia SL: Hidden Markov model for defining genomic changes in lung cancer using gene expression data. OMICS; 2006;10(3):276-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hidden Markov model for defining genomic changes in lung cancer using gene expression data.
  • This method is applied to a lung cancer microarray experiment, including 86 human lung adenocarcinomas.
  • Several regions identified through the HMM are consistent with known recurrent regions of amplification or deletion in this cancer.
  • These findings suggest that genes in these regions may play a major role in the process of carcinogenesis of the lung.
  • [MeSH-major] Gene Expression Profiling. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Markov Chains. Models, Biological
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Humans. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17069508.001).
  • [ISSN] 1536-2310
  • [Journal-full-title] Omics : a journal of integrative biology
  • [ISO-abbreviation] OMICS
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U19 CA-85953
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


85. Martoni A, Marino A, Sperandi F, Giaquinta S, Di Fabio F, Melotti B, Guaraldi M, Palomba G, Preti P, Petralia A, Artioli F, Picece V, Farris A, Mantovani L: Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer; 2005 Jan;41(1):81-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
  • This study compares two cytotoxic regimens comprising the same dose and schedule of cisplatin (CP) plus vinorelbine (VNR) or gemcitabine (GEM) administered under the same schedule to patients with advanced non-small cell lung cancers (NSCLC).
  • Their main characteristics were: male/female ratio 214/58; median age 63 (range 32-77) years; median Karnofsky Performance Status (PS) 80 (range 70-100); stage IIIB 34%, stage IV 61%, recurrent disease 5%; histology - epidermoid 29%, adenocarcinoma 53%, other NSCLC 18%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Vinblastine / analogs & derivatives


91. Larsen JE, Pavey SJ, Passmore LH, Bowman RV, Hayward NK, Fong KM: Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res; 2007 May 15;13(10):2946-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression signature predicts recurrence in lung adenocarcinoma.
  • PURPOSE: Improving outcomes for early-stage lung cancer is a major research focus at present because a significant proportion of stage I patients develop recurrent disease within 5 years of curative-intent lung resection.
  • EXPERIMENTAL DESIGN: To identify a gene signature predictive of recurrence in primary lung adenocarcinoma, we analyzed gene expression profiles in a training set of 48 node-negative tumors (stage I-II), comparing tumors from cases who remained disease-free for a minimum of 36 months with those from cases whose disease recurred within 18 months of complete resection.
  • CONCLUSIONS: We describe a 54-gene signature that predicts the risk of recurrent disease independently of tumor stage and which therefore has potential to refine clinical prognosis for patients undergoing resection for primary adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / genetics. Gene Expression Profiling. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504995.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


92. Keeley SB, Pennathur A, Gooding W, Landreneau RJ, Christie NA, Luketich J: Photodynamic therapy with curative intent for Barrett's esophagus with high grade dysplasia and superficial esophageal cancer. Ann Surg Oncol; 2007 Aug;14(8):2406-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical follow-up, long-term survival, complications, and recurrence were evaluated.
  • Sixteen patients (32%) are alive without recurrence, 15 (30%) are living with residual or recurrent disease and have received additional PDT, and the remainder (38%) died of recurrent EC or other causes and had known recurrence.
  • [MeSH-major] Adenocarcinoma / drug therapy. Barrett Esophagus / complications. Barrett Esophagus / drug therapy. Esophageal Neoplasms / drug therapy. Photochemotherapy / methods

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17534685.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


93. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol; 2005 Apr 10;23(11):2513-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
  • PURPOSE: To evaluate the relationship between mutations of the epidermal growth factor receptor (EGFR) gene and the effectiveness of gefitinib treatment in patients with recurrent lung cancer after pulmonary resection.
  • PATIENTS AND METHODS: We sequenced exons 18-21 of the EGFR gene using total RNA extracted from 59 patients with lung cancer who were treated with gefitinib for recurrent lung cancer.
  • EGFR mutations were significantly more prevalent in females, adenocarcinoma, and never-smokers.
  • Female, never-smoking patients with adenocarcinoma tended to respond better to gefitinib treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Point Mutation. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / physiology


94. Wislez M, Antoine M, Baudrin L, Poulot V, Neuville A, Pradere M, Longchampt E, Isaac-Sibille S, Lebitasy MP, Cadranel J: Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer; 2010 May;68(2):185-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.
  • There is no optimal established therapy for treating advanced or recurrent adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC), and it remains unclear whether chemotherapy achieves therapeutic results comparable to those seen in the more common non-small lung carcinoma subtypes.
  • We demonstrated that demographic data, clinical characteristics and stage at presentation (extrathoracic versus lung metastasis, as well as TNM staging) did not distinguish between the two subtypes.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Mucinous / diagnosis. DNA-Binding Proteins / metabolism. Lung Neoplasms / diagnosis. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19581016.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Quinazolines; 0 / TTF1 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


95. Zhu H, Lam DC, Han KC, Tin VP, Suen WS, Wang E, Lam WK, Cai WW, Chung LP, Wong MP: High resolution analysis of genomic aberrations by metaphase and array comparative genomic hybridization identifies candidate tumour genes in lung cancer cell lines. Cancer Lett; 2007 Jan 8;245(1-2):303-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High resolution analysis of genomic aberrations by metaphase and array comparative genomic hybridization identifies candidate tumour genes in lung cancer cell lines.
  • In this study, metaphase and array comparative genomic hybridization showed good correlation of aberration profiles in lung adenocarcinoma cell lines from patients with different tobacco exposure.
  • Recurrent DNA gains were found at chromosomes 1, 7, 8, 17, 20, and deletions at 1, 3, 8, 9, 10, 12, 17, 18, 19.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Genetic Predisposition to Disease / genetics. Lung Neoplasms / genetics. Nucleic Acid Hybridization / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517066.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


96. Kozak KR, Milne GL, Morrow JD, Cuiffo BP: Hypertrophic osteoarthropathy pathogenesis: a case highlighting the potential role for cyclo-oxygenase-2-derived prostaglandin E2. Nat Clin Pract Rheumatol; 2006 Aug;2(8):452-6; quiz following 456
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient had undergone a right upper lobectomy for a 5 mm, poorly differentiated adenocarcinoma of the lung 4 years previously.
  • DIAGNOSIS: Recurrent non-small-cell lung cancer with adrenal metastasis, hypertrophic osteoarthropathy associated with non-small-cell lung cancer, and hyperprostaglandinuria.
  • [MeSH-minor] Aged. Carcinoma, Non-Small-Cell Lung / complications. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / therapy. Cyclooxygenase 2 Inhibitors / therapeutic use. Fatal Outcome. Female. Humans. Lactones / therapeutic use. Lung Neoplasms / complications. Lung Neoplasms / metabolism. Lung Neoplasms / therapy. Sulfones / therapeutic use

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16932737.001).
  • [ISSN] 1745-8382
  • [Journal-full-title] Nature clinical practice. Rheumatology
  • [ISO-abbreviation] Nat Clin Pract Rheumatol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA77839; United States / NIDDK NIH HHS / DK / DK48831; United States / NIGMS NIH HHS / GM / GM15431; United States / NCRR NIH HHS / RR / RR00095
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Lactones; 0 / Membrane Proteins; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


97. Yao Y, Sun YJ, Zhao H, Guo YW, Lin F, Cai X, Tang XC: [Short-term effects of chemotherapy combined with hydroxycamptothecine and oxaliplatin in treatment of recurrent and metastatic colorectal cancer]. Ai Zheng; 2006 Aug;25(8):1035-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Short-term effects of chemotherapy combined with hydroxycamptothecine and oxaliplatin in treatment of recurrent and metastatic colorectal cancer].
  • BACKGROUND & OBJECTIVE: Although 5-fluarouracil (5-FU)-based chemotherapy has become a standard regimen for treatment of recurrent and metastatic colorectal cancer, the efficacy, as a second line therapy, is not high.
  • This study was to evaluate the short-term effects and toxicity of combination of hydroxycamptothecine (HCPT) plus oxaliplatin (L-OHP) protocol in the treatment of recurrent and metastatic colorectal cancer.
  • METHODS: 47 patients with pathological evidence of recurrent and metastatic colorectal cancer were enrolled and treated with HCPT plus L-OHP regimen for 86 cycles.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Diarrhea / chemically induced. Disease-Free Survival. Female. Follow-Up Studies. Humans. Leukopenia / chemically induced. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Nausea / chemically induced. Neoplasm Recurrence, Local. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965689.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 67656-30-8 / 10-hydroxycamptothecin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


98. Charoentum C: Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year. J Med Assoc Thai; 2006 Jun;89(6):882-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year.
  • A 53-year old non-smoking Thai female was diagnosed with metastatic non-small cell lung cancer to bone.
  • The initial biopsy from the bone lesion showed metastatic adenocarcinoma.
  • This result is consistent with previous reports that the clinical characteristics of female, non-smoker and adenocarcinoma histology seem to predict response to gefitinib.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Neoplasm Recurrence, Local / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16850692.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


99. Silva RG, Dahmoush L, Gerke H: Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. JOP; 2006;7(1):66-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They have a generally poor prognosis and often develop recurrent disease.
  • CASE REPORT: We describe a 69-year-old female with concomitant Duke's C adenocarcinoma of the colon and stage III-C malignant mixed Mullerian tumor that presented with malignant ascites, increasing abdominal girth and a pancreatic head mass.
  • CONCLUSION: The pancreas is a rare site of metastasis and more commonly seen in renal cell carcinoma, melanoma or lung tumors; amongst others.
  • Although ovarian adenocarcinoma has been reported as a primary site of pancreatic metastasis, it has not been previously described originating from a mixed Mullerian tumor of the ovary presenting as a cystic pancreatic head mass.


100. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A: Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol; 2007 Oct 20;25(30):4743-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
  • PURPOSE: Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal antibody, and erlotinib, a reversible, orally available epidermal growth factor receptor tyrosine kinase inhibitor, have demonstrated evidence of a survival benefit in the treatment of non-small-cell lung cancer (NSCLC).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / pathology. Disease-Free Survival. Erlotinib Hydrochloride. Female. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Staging. Pemetrexed. Quinazolines / administration & dosage. Survival Rate. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Glutamates; 0 / Quinazolines; 0 / Taxoids; 04Q9AIZ7NO / Pemetrexed; 15H5577CQD / docetaxel; 2S9ZZM9Q9V / Bevacizumab; 5Z93L87A1R / Guanine; DA87705X9K / Erlotinib Hydrochloride
  •  go-up   go-down






Advertisement